abdullah's picture
Add files using upload-large-folder tool
8de7e09 verified
raw
history blame
62.8 kB
1
00:00:00,610 --> 00:00:05,670
ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุญุถุฑุชู†ุง ุงู„ูŠูˆู… ุนู† tumor
2
00:00:05,670 --> 00:00:12,070
immunology ูˆู…ุดุงุฑุฌ
3
00:00:12,070 --> 00:00:17,990
ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ against tumor cell ุทุจุนุง ูƒู„ู†ุง ุจู†ุนุฑู ุงู†
4
00:00:17,990 --> 00:00:27,770
tumor cell has antigen on their surface ูˆุจุงู„ุชุงู„ูŠ
5
00:00:27,770 --> 00:00:36,130
these antigens are foreign antigens ูˆุจุงู„ุชุงู„ูŠ
6
00:00:36,130 --> 00:00:43,430
ุงู„ุฌุณู… ุจูŠุนุชุจุฑู‡ุง as foreign cells ูˆู„ุงุจุฏ ู…ู† ุงู†ู‡ ูŠุดูŠุฑ
7
00:00:43,430 --> 00:00:54,770
ููŠู‡ ุชุตุฏูŠ ู„ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง ุงู„
8
00:00:54,770 --> 00:00:55,730
tumor specific
9
00:00:58,510 --> 00:01:02,690
transplantation antigen ู‡ูŠ ุงู„ุงู†ุชุฌู†ุงุช ุงู„ุชูŠ ุชุธู‡ุฑ ุนู„ู‰
10
00:01:02,690 --> 00:01:07,830
ุณุทุญ ุฎู„ุงูŠุง tumor ูˆูˆุฌุฏูˆู‡ุง
11
00:01:07,830 --> 00:01:12,390
in variety of animal species tumor specific
12
00:01:12,390 --> 00:01:17,830
transplantation antigen ู„ุฃู†ู‡ู… ู‡ูŠุฏุฎู„ูˆุง ุนู„ู‰ ุชุนุฑูŠูุงุช ู‡ุฐู‡
13
00:01:17,830 --> 00:01:23,870
ุงู„ุงู†ุชุฌู†ุงุช tumor antigen ู…ู…ูƒู† ุชุดุชุฑูƒ ู…ุน ุงู„ tumor
14
00:01:23,870 --> 00:01:24,290
cell
15
00:01:28,020 --> 00:01:33,300
ุชุดุชุฑูƒ ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู
16
00:01:33,300 --> 00:01:35,480
ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„
17
00:01:35,480 --> 00:01:35,880
ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู
18
00:01:35,880 --> 00:01:39,600
ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„
19
00:01:39,600 --> 00:01:43,560
ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู
20
00:01:43,560 --> 00:01:44,340
ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„
21
00:01:44,340 --> 00:01:50,080
ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„ ู…ุฎุชู„ู ุจุดูƒู„
22
00:01:50,080 --> 00:01:55,800
ู…ุฎุชู„ู ุจุดูƒู„ Demonstration of Tumor-Specific
23
00:01:55,800 --> 00:01:59,980
Antigen of Chemically Induced Tumor ุฃูˆู„ ู…ุง ุงูƒุชุดููˆุง
24
00:01:59,980 --> 00:02:06,400
ุฑุฏุฉ ูุนู„ ุฌุณู… ุงู„ู…ู„ุงุนูŠุฉ ููŠ ุงู„ .. against tumor
25
00:02:06,400 --> 00:02:15,560
antigen ู…ู† ุฎู„ุงู„ ุชุฌุฑุจุฉ ุนู„ู‰ ุงู„ mice ุงู„ุชุฌุฑุจุฉ ูƒุงู†ุช
26
00:02:15,560 --> 00:02:25,710
ูƒุงู„ุขุชูŠ ุนู…ู„ูˆุง tumor ููŠ ุงู„ู€ mouse ู…ู† ุฎู„ุงู„ ุฏู‡ู† ุงู„
27
00:02:25,710 --> 00:02:32,450
skin of the mouse by methyl chloranthrene ูˆุจุงู„ุชุงู„ูŠ
28
00:02:32,450 --> 00:02:38,730
ุงุณุชูƒูˆู† ุงู„ tumor they excise the tumor ูˆุนู…ู„ูˆุง ู…ู†ู‡
29
00:02:38,730 --> 00:02:44,990
tumor cell suspension ูˆุจุนุฏ ู‡ูŠูƒ they inject the
30
00:02:44,990 --> 00:02:50,220
prepared tumor cell into a new mouseุฃูŠุถุง ุชูƒูˆู†ุช
31
00:02:50,220 --> 00:02:57,060
tumor , they excise the tumor ูˆ they challenge the
32
00:02:57,060 --> 00:03:02,660
mouse with the same tumor ูˆุฌุฏูˆุง ุงู†ู‡ there is no
33
00:03:02,660 --> 00:03:03,760
tumor growth
34
00:03:07,990 --> 00:03:11,330
Injection of prepared tumor cell into a new
35
00:03:11,330 --> 00:03:17,910
mouse Excise a growing tumor ุฃูŠุถู‹ุง Challenge with
36
00:03:17,910 --> 00:03:22,510
different tumor cells With tumor cells ู†ุญูˆ ุงู„ู€
37
00:03:22,510 --> 00:03:30,630
tumor will grow ุจุจุณุงุทุฉ ุฎุทูˆุงุช ุงู„ุชุฌุฑุจุฉ ูƒุงู†ุช ูƒุงู„ุขุชูŠ
38
00:03:30,630 --> 00:03:36,070
ุฐูƒุฑู†ุงู‡ุง ุฅู†ู…ุง ู†ุดุฑุญู‡ุง ุนู„ู‰ ุตูˆุฑุฉ ูƒุงู„ุขุชูŠ ู‡ูŠ ุนุจุงุฑุฉ ุนู†
39
00:03:36,070 --> 00:03:40,500
mouse with chemically carcinogenic induced tumor
40
00:03:40,500 --> 00:03:48,180
ุฏู‡ุงู†ู‡ุง ุฏู‡ ู‡ูˆ ุงู„ skin by ash ุงู„ู„ูŠ ู‡ูˆ carcinogenic
41
00:03:48,180 --> 00:03:53,940
agent ูุชูƒูˆู† ุงู„ cancer ุฃุฎุฏู†ุงู‡ุง ูˆ ุนู…ู„ู†ุง ู…ู†ู‡ุง tumors
42
00:03:53,940 --> 00:04:00,240
cell suspension ูุทุจุนุง
43
00:04:00,240 --> 00:04:08,550
ุญู‚ู†ู‡ุง ู„ู„ูุนู„ ู…ุงุดูŠ the same the same mouse ุญู‚ู†ู‡ุง
44
00:04:08,550 --> 00:04:17,410
ุงู„ู‡ ุซู… ุฑุฌุนู†ุง ุชุงู†ูŠ ูˆุญุทูŠู†ุง ุงู„ู‡ tumor cell ูˆุฌุฏู†ุง ุงู†
45
00:04:17,410 --> 00:04:26,890
ุงู„ tumor cell ู„ู… ุชู†ู…ูˆ ุฏู„ูŠู„ ุนู„ู‰ ุงู† ุงู„ tumor cell
46
00:04:26,890 --> 00:04:31,490
ุงู„ู„ูŠ ุฏุฎู„ุช ุชุตุฏู‰ ู„ู‡ุง ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ูˆูƒูˆู† ุงู„ vector
47
00:04:31,490 --> 00:04:37,790
cell ุนู…ู„ู†ุง ุงู„ tumor ู…ุฑุฉ ุชุงู†ูŠุฉ ุงู„ tumor has been
48
00:04:37,790 --> 00:04:44,210
rejected the same cell ู‡ูˆ tumors ุงู„ุญู‚ู†ู‡ุง for
49
00:04:44,210 --> 00:04:57,290
syngeneic mice ุจุณ ููŠ ู‡ุฐู‡ ุงู„ุญุงู„ุฉ ู„ู…ุง ู„ู…ุง ูŠุนู†ูŠ ุนู…ู„ู†ุง
50
00:04:57,290 --> 00:05:04,330
ุชูƒูˆู† ุงู„ tumor ู„ูƒู† ู„ู…ุงุฐุงุŸ ู„ุฃู†ู‡ ู„ู… ูŠุฑู‰ ุงู„ู€ tumor ู…ู†
51
00:05:04,330 --> 00:05:09,650
ู‚ุจู„ ู‡ุฐุง ุงู„ู€ mouse ู„ูƒู† ู„ูˆ ุฃุฎุฏู†ุง ุงู„ุฎู„ุงูŠุง ุงู„ู…ู†ุงุนูŠุฉ
52
00:05:09,650 --> 00:05:12,950
ุงู„ุชูŠ ุชุชูƒูˆู†ุช ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ุงุดุชุบู„ ูˆุฃุฎุฏู†ุง ุงู„ุฎู„ุงูŠุง
53
00:05:12,950 --> 00:05:18,430
ุงู„ู…ู†ุงุนูŠุฉ ุงู„ุชูŠ ุชูƒูˆู†ุช ุนู†ุฏู‡ ูˆุญู‚ู†ู‡ุง ููŠ fire ุชุงู†ูŠ ู…ู†
54
00:05:18,430 --> 00:05:22,770
ุฎู„ุงู„ ุฏู‡ ู‡ูˆ adoptively transfer T cell ุฎุฏู†ุง ุงู„ุฎู„ุงูŠุง
55
00:05:22,770 --> 00:05:24,790
ุงู„ู…ู†ุงุนูŠุฉ ุงู„ู…ุชู…ุซู„ุฉ ุจุงู„ู€ T cells
56
00:05:28,050 --> 00:05:31,230
ุนู…ู„ู†ุง challenge ูŠุนู†ูŠ ุงุนุทูŠู†ุง .. ูƒูˆู†ู†ุง tumor ุนู†ุฏู‡
57
00:05:31,230 --> 00:05:35,490
ู…ุฑุฉ ุชุงู†ูŠุฉ ูŠุนู†ูŠ ู†ู„ุงู‚ูŠ ุงู† tumor has been eradicated
58
00:05:35,490 --> 00:05:41,810
ุจู…ุนู†ู‰ ู„ู… ุชู†ู…ูˆ ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง ูŠุนู†ูŠ ุงู„ูุงุฑู‚ ุงู„ู„ูŠ ุนู†ุฏู‡
59
00:05:41,810 --> 00:05:44,970
tumor ู„ู…ุง ู†ุฎู„ู†ุงู‡ ุจุงู„ุงุฏุงุก .. ุจุงู„ .. ุจุงู„ .. ุจุงู„ team
60
00:05:44,970 --> 00:05:51,170
for science ุงู„ู„ูŠ ุงุชูƒูˆู†ุช ุนู†ุฏู‡ ู…ุงุดูŠ ูุฏู‡ ู‡ูˆ ุนู„ู‰ ุทูˆู„
61
00:05:51,170 --> 00:05:59,070
ุตุงุฑ ููŠ eradication ุงู„ุฃู…ูŠู† ู„ู„ tumor ุงู„ู„ูŠ ู…ูˆุฌูˆุฏ ุฏู„ูŠู„
62
00:05:59,070 --> 00:06:03,650
ุนู„ู‰ ุงู† ููŠ ุฌู‡ุงุฒ ู…ู†ู‡ุง ู‚ุงุนุฏ ุจูŠุดุชุบู„ ูˆุงู†ู‡ ููŠ ุนู„ุงู‚ุฉ
63
00:06:03,650 --> 00:06:10,910
ู…ุซุจุชุฉ ุจูŠู† ุงู„ immune response ูˆ tumor cell tumor
64
00:06:10,910 --> 00:06:17,930
immunology ู‡ุฏูู‡ุง ู‡ูˆ ู…ุนุฑูุฉ ุงู„ุนู„ุงู‚ุฉ ู…ุง ุจูŠู† ุงู„ host
65
00:06:17,930 --> 00:06:22,890
and tumor ุฃูŠุถู‹ุง using the immune response to tumor
66
00:06:22,890 --> 00:06:29,050
for diagnosis for prophylaxis and for therapy ู‡ูˆ
67
00:06:29,050 --> 00:06:36,330
ุงู„ุงู†ุชุฌูŠู† ุทุจุนุง ูƒูŠููŠุฉ ุชูƒูˆูŠู†ู‡ุง ุจุชุชู… ุฎู„ุงู„ mutation
68
00:06:36,330 --> 00:06:42,550
genetic activation clonal amplification
69
00:06:42,550 --> 00:06:48,910
chromosomal deletion and translocation ูƒู„ู‡ุง ุนุจุงุฑุฉ
70
00:06:48,910 --> 00:06:53,730
ุนู† ุนู…ู„ูŠุงุช ุจุชุคุฏูŠ ุฅู„ู‰ mutation ูˆุจุงู„ุชุงู„ูŠ ุจุชูƒูˆูŠู† ู„
71
00:06:53,730 --> 00:06:57,550
tumor antigen some tumor antigen are unique to
72
00:06:57,550 --> 00:07:02,510
cancerous ูŠุนู†ูŠ ูู‚ุท ู…ูˆุฌูˆุฏุฉ ุนู„ู‰ ุฎู„ุงูŠุง ุงู„ุณุฑุทุงู†ูŠุฉ ูˆ
73
00:07:02,510 --> 00:07:09,110
other ู‡ูŠ ู…ุดุงุจู‡ุฉ ู„ู€ tumor cell antigen ูŠุนู†ูŠ ู…ูˆุฌูˆุฏ
74
00:07:09,110 --> 00:07:16,270
ุจุชุดุจูŠู‡ ุงู„ู„ูŠ ู‡ูŠ ุงูŠุด ุงู„ ุงู„ normal cell antigen ู„ูƒู†ู‡ุง
75
00:07:16,270 --> 00:07:22,170
ุจุชุบุทูŠ ุงู„ุฎู„ุงูŠุง ุชุบุทูŠุฉ ูƒุงู…ู„ุฉ ุฃูˆ ุฌุฒุฆูŠุฉ and these
76
00:07:22,170 --> 00:07:29,430
either by more expression on cancer cells ู„ูƒู† ุตุงุฑ
77
00:07:29,430 --> 00:07:32,710
ููŠู‡ expression ุฒูŠุงุฏุฉ ุนู† ุงู„ู„ุงุฒู… ู„ู‡ุฐู‡ ุงู„ุงู†ุชูŠุฌู†ุงุช
78
00:07:32,710 --> 00:07:38,010
ุนู„ู‰ ุณุทุญ ุงู„ุฎู„ูŠุฉ ุงู„ุณุฑุทุงู†ูŠุฉ ูˆุงู…ุซู„ุฉ ุนู„ู‰ ุฐู„ูƒ ูƒุซูŠุฑ ู…ู†ู‡ุง
79
00:07:38,010 --> 00:07:41,470
ุงู„ human epidermal growth factor ุงู„ุฑูŠุณุจุชูˆุฑ ุงู„ู„ูŠ
80
00:07:41,470 --> 00:07:45,370
ุจูŠุฒูŠุฏ ุงู„ expression ุชุจุนู‡ ููŠ ุงู„ ovarian and breast
81
00:07:45,370 --> 00:07:51,190
cancer ุจุนุถ ุงู„ tumor antigen are present on
82
00:07:51,190 --> 00:07:55,170
embryonic cell ู„ูƒู†ู‡ุง ู…ุด ู…ูˆุฌูˆุฏุฉ ุนู„ู‰ ุงู„ normal other
83
00:07:55,170 --> 00:08:01,190
cells ุฒูŠ ุงู„ oncofetal antigen ุทู…ูˆุฑ ุงู„ุงู†ุชุฌูŠู† ูŠู…ูƒู† ุฃู†
84
00:08:01,190 --> 00:08:05,850
ูŠูƒูˆู† ู…ุตุฏุฑ ู…ู† ุงู„ุฌูŠู†ุงุช ุงู„ู…ุชูˆุณุทุฉ ุฃูŠุถู‹ุง ุฏู„ูŠู„ ุนู„ู‰ ุงู†ู‡ ููŠ
85
00:08:05,850 --> 00:08:10,610
ู…ูˆุงู‚ุน ุญุฑุงุฑุฉ ู„ู„ุชุบูŠูŠุฑ ูˆู‡ู†ุงูƒ
86
00:08:10,610 --> 00:08:11,710
ู‚ู„ูŠู„ ู…ู† ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ
87
00:08:11,710 --> 00:08:12,030
ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ
88
00:08:12,030 --> 00:08:14,290
ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ
89
00:08:14,290 --> 00:08:14,990
ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ
90
00:08:14,990 --> 00:08:15,510
ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ ุนู…ู„ูŠุฉ
91
00:08:21,440 --> 00:08:24,420
ุงู„ุชูŠ ุชุณุจุจ ููŠ ุชุญูˆูŠู„ ุงู„ tumor ุจุดูƒู„ ุฎุงุทุฆ ู…ุซู„ ุงู„ู€
92
00:08:24,420 --> 00:08:30,680
Ultraviolet ูˆุงู„ู€ X-ray ุฅุดุนุงุนูŠุฉ ูƒุงุฑุณูŠู†ูˆุฌูŠู† ูŠู…ูƒู† ุฃู†
93
00:08:30,680 --> 00:08:35,840
ูŠุณุจุจ ููŠู‡ ุชุญูˆูŠู„ ูƒู„ูˆู†ูŠ ูƒุงุฑุณูŠู†ูˆุฌูŠู† ูŠุนู…ู„ ุชุญูˆูŠู„ ูƒู„ูˆู†ูŠ
94
00:08:35,840 --> 00:08:42,000
ู„ุฌูŠู†ุงุช ูู‚ุท ุงู„ู„ูŠ ุจุณุจุจ ุชุญูˆูŠู„ ุฌูŠู†ุงุช ูŠู…ุชู„ุฆ ู…ุตุงุฏุฑ
95
00:08:42,000 --> 00:08:42,320
ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ
96
00:08:42,320 --> 00:08:43,620
ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ
97
00:08:43,620 --> 00:08:45,860
ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ
98
00:08:45,860 --> 00:08:50,670
ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ู…ุตุงุฏุฑ ุจุชุคุฏูŠ ุฅู„ู‰ ุงูŠุด
99
00:08:50,670 --> 00:08:57,930
ุนู…ู„ูŠุฉ clonal amplification ู„ุฎู„ูŠุฉ ู…ุงุดูŠ ู„ูŠุด ู„ุฃู†ู‡
100
00:08:57,930 --> 00:09:04,150
ุงู„ุฌูŠู†ุงุช ุงู„ู„ูŠ ุจุชุญุชูˆูŠ ุนู„ู‰ ุชูุฑุน ูˆุงุญุฏุฉ ู…ุงุดูŠ ู‡ูŠ ุงู„ู„ูŠ
101
00:09:04,150 --> 00:09:08,110
ุนู…ู„ุช clonal amplification carcinogen ู…ุฑุฉ ุชุงู†ูŠุฉ
102
00:09:08,110 --> 00:09:14,550
ุจูŠุคุฏูŠ ุฅู„ู‰ mutation ู…ุงุดูŠ of genes ูˆุจุงู„ุชุงู„ูŠ ู‡ุฐู‡
103
00:09:14,550 --> 00:09:19,170
ุงู„ุฌูŠู†ุงุช ุงู„ุชูŠ ุชุญู…ู„ ุจู‡ุง ุจูˆุงุณุทุฉ ุฎู„ุงูŠุง ู…ุนูŠู†ุฉ ุชุฏู‘ูŠ
104
00:09:19,170 --> 00:09:22,870
ู†ู‚ู„ูˆู„ุฉ ุงู„ amplification of the single cell
105
00:09:22,870 --> 00:09:28,450
ุงู„ู…ุชุญุณุณุฉ ู„ู„ู…ูŠูˆุชูŠุดู† tumor antigen are well
106
00:09:28,450 --> 00:09:33,330
demonstrated by viruses ูƒู…ุงู† ุจุนุถ ุงู„ููŠุฑูˆุณุงุช virus
107
00:09:33,330 --> 00:09:39,570
induced tumor ุจูŠุณู…ูˆู‡ู… oncogenic viruses ูˆู‡ุฐู‡ ุจุชุคุฏูŠ
108
00:09:39,570 --> 00:09:44,910
ุฅู„ู‰ ุทุจุนุง ุฃุธู‡ุฑุช cross reactivity among tumors
109
00:09:44,910 --> 00:09:54,010
induced by the same viruses ุงู„ุฌุฏูˆู„ ุงู„ุชุงู„ูŠ ุจูŠุจูŠู† ู„ู†ุง
110
00:09:54,010 --> 00:09:59,440
ุฃู†ูˆุงุน tumor antigen ุฒูŠ ู…ุง ุฃู†ุชู… ุดุงูŠููŠู† ููŠ embryonic
111
00:09:59,440 --> 00:10:04,000
ู‚ู„ู†ุง ุชุธู‡ุฑ ุงู„ู€ oncofetal antigen ุฒูŠ ุงู„ melanoma
112
00:10:04,000 --> 00:10:11,960
associated gene ุงู„ู„ูŠ ู‡ูˆ ุฑู‚ู… ูˆุงุญุฏ ูˆุงุชู†ูŠู† ุฒูŠ ุงู„
113
00:10:11,960 --> 00:10:14,820
carcinogenic embryonic antigen ุฒูŠ ุงู„ alpha
114
00:10:14,820 --> 00:10:20,730
-fetoprotein ูƒู„ู‡ุง ุนุจุงุฑุฉ ุนู† ุงู„ู„ูŠ ู‡ูˆ ุงู†ุชูŠุฌู†ุงุช ุจุชุธู‡ุฑ
115
00:10:20,730 --> 00:10:25,290
ุนู„ู‰ overexpressed ุงู„ู…ูุฑูˆุถ ุฃู†ู‡ุง ุจุชุธู‡ุฑ ุนู„ู‰ ุงู„
116
00:10:25,290 --> 00:10:27,930
embryonic life ู„ูƒู†ู‡ุง ุจุชุธู‡ุฑ ุนู„ู‰ ุงู„ tumor cell
117
00:10:27,930 --> 00:10:35,270
differentiation ุฒูŠ prostate specific antigen ูˆ
118
00:10:35,270 --> 00:10:41,830
ุงู„ุชูŠุฑูˆู†ูŠุฒูŠู† ูˆ ุงู„ human epidermal growth factor
119
00:10:41,830 --> 00:10:47,710
ู…ุงุดูŠ ูˆูŠูˆุฌุฏ antigenุงุช ุฒูŠ ุงู„ always ู‡ู†ุงูƒ ุงู„ู€
120
00:10:47,710 --> 00:10:50,290
Clonal Amplification ูˆู‡ู†ุงูƒ ุงู„ู€ Point MutationุŒ
121
00:10:50,290 --> 00:10:54,550
ุชุฑูƒุฒูˆุง ููŠู‡ู… ูˆุงุญุฏ ูˆุงุญุฏ Normal Cellular Gene
122
00:10:54,550 --> 00:11:00,290
Products Expressed During Embryogenesis ู‡ุฐุง ุฃูˆู„
123
00:11:00,290 --> 00:11:03,710
ูˆุงุญุฏ ุงู„ู„ูŠ ู‚ู„ู†ุง ุงู„ู„ูŠ ู‡ูˆ ุงู„ู€ Oncofetal Antigen ุฒูŠ
124
00:11:03,710 --> 00:11:06,830
ุงู„ู€ Melanoma Associated Antigen
125
00:11:10,100 --> 00:11:15,100
ูˆุทุจุนุง ู‡ุฐู‡ ุนุจุงุฑุฉ ุนู† ุงู†ุชูŠุฌู†ุงุช ู…ู…ูƒู† ู†ุดุชุบู„ู‡ุง ู†ุณุชุฎุฏู…ู‡ุง
126
00:11:15,100 --> 00:11:19,820
ูƒ vaccine ู„ุฃู†ู‡ their expression is shared ูŠุนู†ูŠ
127
00:11:19,820 --> 00:11:28,060
ุจุชุดุชุฑูƒ ูƒู„ ุงู„ู…ูŠู„ุงู†ูˆู…ุฉ ุจูˆุฌูˆุฏ ู‡ุฐู‡ ุงู„ุงู†ุชูŠุฌูŠู†ุงุช ูุงุญู†ุง
128
00:11:28,060 --> 00:11:31,920
ุนุดุงู† ู†ุดุชุบู„ ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ู…ู…ูƒู† ู†ุงุฎุฏู‡ุง ูˆุทุจุนุง ู†ุญู‚ู†ู‡ุง
129
00:11:31,920 --> 00:11:37,720
ูƒุงู†ุชูŠุฌูŠู†ุงุช ุจุงู„ุชุงู„ูŠ ุจุนุฏ ุทุจุนุง ู…ุง ู†ุนู…ู„ู‡ุง
130
00:11:38,900 --> 00:11:43,320
Inactivation ูˆุจุงู„ุชุงู„ูŠ ุจู†ุดุฑ ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ู…ู† ุฎู„ุงู„ู‡
131
00:11:43,320 --> 00:11:48,860
Carcinoembryonic antigen CEA ุทุจุนุง
132
00:11:48,860 --> 00:11:54,420
ูˆุฌุฏูˆู‡ ูŠุนู†ูŠ ู‡ุฐุง ุนุจุงุฑุฉ ุนู† protein ุบุงู„ุจุง found in
133
00:11:54,420 --> 00:12:00,800
serum of patients with cancer of GIT ุฒูŠ ุงู„ colon
134
00:12:00,800 --> 00:12:10,650
cancer ูˆุฒูŠุงุฏุฉ ุงู„ level of CEA ูˆุฌุฏูˆู‡ุง ููŠ ุงู„ุฃู…ุฑุงุถ
135
00:12:10,650 --> 00:12:14,630
ุฃุฎุฑู‰ ุบูŠุฑ ุงู„ู„ูŠ ู‡ูˆ ุงู„ colon cancer ุงู„ู„ูŠ ู‡ูŠ non
136
00:12:14,630 --> 00:12:18,970
specific or non-neoplastic diseases ุฒูŠ ุงู„
137
00:12:18,970 --> 00:12:24,190
ulcerative colitis ูˆ ุงู„ pancreatitis ุงู„ู†ุงุณ ุฏูˆู„ุฉ
138
00:12:24,190 --> 00:12:29,750
they don't have cancer ูˆุจุงู„ุชุงู„ูŠ this test is non
139
00:12:29,750 --> 00:12:36,000
specific ุฃู„ูุง ููŠุชูˆ ุจุฑูˆุชูŠู† ู‡ุฐุง normally present at
140
00:12:36,000 --> 00:12:40,580
high concentration ููŠ ุงู„ู€ fetal maternal serum ูˆ
141
00:12:40,580 --> 00:12:47,220
it's absent ููŠ ุงู„ normal adult individual ู„ูƒู†ู‡
142
00:12:47,220 --> 00:12:53,340
ู…ูˆุฌูˆุฏ ููŠ ุงู„ู†ุงุณ ุงู„ู„ูŠ ุนู†ุฏู‡ู… hepatoma and testicular
143
00:12:53,340 --> 00:12:56,340
teratocarcinoma
144
00:12:59,290 --> 00:13:04,150
ุงู„ุซุงู†ูŠ ู‡ูˆ ุงู„ู€ Mutant Cellular Gene Product ู†ุงุชุฌ ุนู†
145
00:13:04,150 --> 00:13:09,370
ู…ูŠูˆุชูŠุดู† ุฌูŠู† ุตุงุฑ ู„ู‡ ู…ูŠูˆุชูŠุดู† ูˆููŠ ุฃู…ุซู„ุฉ ูƒุซูŠุฑุฉ ุนู„ู‰ ุฐู„ูƒ
146
00:13:09,370 --> 00:13:15,110
ู…ู†ู‡ุง ููŠ ุงู„ู€CML ุงู„ุชุงูŠุฑูˆุณูŠู† ูƒุงูŠู†ูŠุฒ activity ุจุชุฒูŠุฏ
147
00:13:15,110 --> 00:13:20,510
ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠู‡ ุงู„ู„ูŠ ู‡ูˆ uncontrolled cellular
148
00:13:20,510 --> 00:13:25,650
proliferation ูˆู„ูˆ ุงุณุชุฎุฏู…ู†ุง inhibitor ู„ู„ุฌูŠู† ุชุจุน ุงู„
149
00:13:25,650 --> 00:13:33,490
PCR APL ุงู„ุฌูŠู† ุงู„ูƒุงูŠู…ุฑูŠูƒูŠ ุงู„ู„ูŠ ุจูŠุชูƒูˆู† ููŠ ุงู„ู€CML ุฃูˆ
150
00:13:33,490 --> 00:13:39,150
ู…ุง ูŠุณู…ู‰ ุจุงู„ููŠู„ุงุฏูŠู„ููŠุง ูƒุฑูˆู…ูˆุณูˆู… ุงุชุดูˆู†
151
00:13:39,150 --> 00:13:43,270
ุฃูŠ promise for inducing a complete hematological
152
00:13:43,270 --> 00:13:49,150
response ู„ูˆ ููŠ ู†ุฌุงุญ ุชู… ุจุงุณุชุฎุฏุงู… ุงู„ู€inhibitor ููŠ
153
00:13:49,150 --> 00:13:57,770
ุนู…ู„ูŠุฉ ูƒุจุญ ุฌู…ุงุญ ุงู„ู„ูŠ ู‡ูˆ ุงู„ู€CML disease ุทุจุนุง ูˆุงู„ูŠูˆู…
154
00:13:57,770 --> 00:14:03,750
ุจูŠุนุชุจุฑูˆู‡ุง targeting therapy ุงู„ูŠูˆู… ูŠุนู†ูŠ ุฃุธู‡ุฑ ู†ุฌุงุญุงุช
155
00:14:03,750 --> 00:14:08,910
ูƒุซูŠุฑุฉ ูˆู…ุฑุถู‰ ุณูŠุฃู…ุงู„ ุงุณุชุบู†ูˆุง ุบุงู„ุจุง ุนู† ุงู„
156
00:14:08,910 --> 00:14:13,930
chemotherapy ุงู„ู…ุซุงู„
157
00:14:13,930 --> 00:14:19,610
ุงู„ุขุฎุฑ ุนู† mutant cellular gene ู‡ูˆ ุงู„ mutation ุงู„ู„ูŠ
158
00:14:19,610 --> 00:14:25,050
ุจุชุตูŠุฑ ููŠ ุงู„ P53 protein ุทุจุนุง ุงู„ P53 mutation
159
00:14:29,510 --> 00:14:35,210
ุจุชุธู‡ุฑ ุจุชุธู‡ุฑ ุงู† it changes in p53 ูŠุนู†ูŠ ุงู„ู†ุชูŠุฌุฉ
160
00:14:35,210 --> 00:14:42,770
changes in p53 ูˆ ุงู„ protein ุงู„ู„ูŠ ุจูŠุชูƒูˆู† ุบุงู„ุจุง
161
00:14:42,770 --> 00:14:47,170
ุจูŠุดุชุบู„ as a suppressor of cellular growth ู‡ุฐุง ููŠ
162
00:14:47,170 --> 00:14:55,510
ุงู„ูˆุถุน ุงู„ุทุจูŠุนูŠ ุงู† ุงู„ P53 code for protein ุจูŠุนู…ู„
163
00:14:55,510 --> 00:15:03,870
stopping ู„ู„ู€ cell cycle at certain stage
164
00:15:03,870 --> 00:15:08,650
ูŠูˆู… ูŠุตูŠุฑ ููŠู‡ ุฎู„ู„ ุจูŠูˆู‚ู ูŠูˆู… ูŠุตูŠุฑ ููŠู‡ ู…ูŠูˆุชูŠุดู† ุจูŠุทู„ุน
165
00:15:08,650 --> 00:15:12,730
ู„ู†ุง ุจุฑูˆุชูŠู† ุฃุตู„ุง ููŠู‡ ู…ูŠูˆุชูŠุดู† ุงู„ู„ูŠ ู…ู…ูƒู† ูŠุนู…ู„ ูŠุดุชุบู„
166
00:15:12,730 --> 00:15:20,670
ุงู„ุณุจุฑุณ ูˆุงู„ุณู„ูŠุฌุฑุงุซ tumor immunity in vivo can be
167
00:15:20,670 --> 00:15:25,710
induced by vaccination against mutant p53 peptide
168
00:15:25,710 --> 00:15:35,450
ู„ูˆ ุฃุนุทูˆุง ุงู„ p53 peptide ู…ุน ุงู„ IL-12 ุจูŠุนุชุจุฑ ู‡ุฐุง ูƒ
169
00:15:35,450 --> 00:15:36,190
vaccine
170
00:15:39,970 --> 00:15:43,250
ูˆูˆุฌุฏูˆุง ุงู† ุงู„ู€ T lymphocyte directed against normal
171
00:15:43,250 --> 00:15:47,090
p53 might preferentially destroy a tumor cell ุทุจุนุง
172
00:15:47,090 --> 00:15:49,970
ู‡ุฐุง ุงู„ูƒู„ุงู… ุจู†ุดู‡ุฏ ุงู„ T lymphocyte ูˆT lymphocyte
173
00:15:49,970 --> 00:15:53,610
ุจุชู‡ุงุฌู… ุงู„ tumor cell ู‡ูˆ ุจุงู„ุชุงู„ูŠ ู…ู…ูƒู† ูŠุณุชุฎุฏู… ูƒ
174
00:15:53,610 --> 00:16:01,770
vaccine ู‡ูˆ ูˆ IL-12 ู…ุน ุจุนุถ ู…ู† ุญู‚ู†ู‡ ู…ุน ุจุนุถ ุชู„ุงุชุฉ
175
00:16:01,770 --> 00:16:05,310
tumor antigen encoded by oncogene ุทุจุนุง ูƒู„ู†ุง ุจู†ุนุฑู
176
00:16:05,310 --> 00:16:08,830
ุงู† ุงู„ oncogene ู‡ูˆ ุนุจุงุฑุฉ ุนู†
177
00:16:13,680 --> 00:16:19,240
ูˆุจุงู„ุชุงู„ูŠ ุฌุงูŠ ุจุนุฏ ู…ุง ุตุงุฑ ููŠู‡ mutation ููŠ ุงู„ normal
178
00:16:19,240 --> 00:16:23,020
gene ูˆ ุงู„ normal gene ุจูŠุณู…ูˆู‡ proto-oncogene ุงู„ู„ูŠ
179
00:16:23,020 --> 00:16:28,160
ูŠูˆู… ู…ุง ูŠุชุญูˆู„ ู„ proto-oncogene ู„ู€ C-oncogen
180
00:16:30,930 --> 00:16:35,950
ุจูŠุชูƒูˆู† ุงู„ู„ูŠ ู‡ูˆ as a mutation ุทุจุนุง as a result of
181
00:16:35,950 --> 00:16:42,990
mutation ุจูŠุตูŠุฑ ููŠู‡ ุงู„ู„ูŠ ู‡ูˆ tumor ูˆุทุจุนุง ููŠู‡ ุณุฌู„ุฉ
182
00:16:42,990 --> 00:16:48,050
ุญุงู„ุงุช ูƒุซูŠุฑุฉ ู…ู† ุฎู„ุงู„ ุนู„ุงู‚ุฉ ุงู„ tumor ุงูˆ ุงู„ viruses
183
00:16:48,050 --> 00:16:51,890
ุจุงู„ุฃุด ุจุงู„
184
00:16:55,500 --> 00:17:02,580
ุฃูŠ ู‡ุฏุง ู‡ูŠ ู†ุธุฑูŠุฉ ุงู„ุงู†ูƒูˆุฌูŠู† ุชู‚ุชุฑุญ ุฃูˆ postulate that
185
00:17:02,580 --> 00:17:06,780
such proto-oncogene ูŠูˆู… ุจุณู„ู‡ mutation or activation
186
00:17:06,780 --> 00:17:10,300
display increased expression or inappropriate
187
00:17:10,300 --> 00:17:14,440
expression ุจุณู„ู‡ increased ุงูˆ inappropriate
188
00:17:14,440 --> 00:17:18,500
expression ู„ู„ู€ mutated form of their gene a
189
00:17:18,500 --> 00:17:22,480
product ูˆุจุงู„ุชุงู„ูŠ ุจูŠุณุงู‡ู… ูƒุซูŠุฑ ููŠ ุชุญูˆูŠู„ ุงู„ุฎู„ุงูŠุง
190
00:17:22,480 --> 00:17:28,100
ุงู„ุทุจูŠุนูŠุฉ ุงู„ู‰ ุฎู„ุงูŠุง ุณุฑุทุงู†ูŠุฉ ูˆุงู„ู„ูŠ ุจูŠุชูƒูˆู† cancer
191
00:17:28,100 --> 00:17:31,680
ุทุจุนุง ุนู…ู„ูŠุฉ ุงู„ mutation ุจุชุชู… ู…ู† ุฎู„ุงู„ ุงู„ chromosomal
192
00:17:31,680 --> 00:17:34,640
translocation point mutation gene amplification
193
00:17:34,640 --> 00:17:43,250
ูˆู‡ูƒุฐุง ูˆู‡ุฐู‡ ุญุงู„ุงุช ูƒุซูŠุฑุฉ ู…ุงุดูŠ ุตุงุฑ ููŠู‡ุง activation ู„ู€
194
00:17:43,250 --> 00:17:48,130
cellular proto-oncogene in a human ุฃูŠ CMEC ุตุงุฑ ู„ู‡
195
00:17:48,130 --> 00:17:56,170
Genetic Rearrangement ูˆุชุบูŠุฑุช ุตุงุฑ ููŠู‡
196
00:17:56,170 --> 00:17:59,410
Translocation ู…ุง ุจูŠู† ูƒุฑูˆู…ูˆุณูˆู…ุงุช ุชู…ุงู†ูŠุฉ ูˆุฃุฑุจุน ุนุดุฑุฉ ุฃูˆ
197
00:17:59,410 --> 00:18:02,190
ุซู…ุงู†ูŠุฉ ูˆุงุซู†ูŠู† ุฃูˆ ุซู…ุงู†ูŠุฉ ูˆุงุซู†ูŠู† ูˆุนุดุฑูŠู† ูˆุนู…ู„ูˆุง
198
00:18:02,190 --> 00:18:08,860
ุญุงุฌุฉ ุจูŠุณู…ูˆู‡ุง Perkins lymphoma APL ุฃูŠุถู‹ุง ุตุฑู„ู‡
199
00:18:08,860 --> 00:18:12,920
Genetic Transformation ุฃูˆ Rearrangement ู…ู† ุฎู„ุงู„
200
00:18:12,920 --> 00:18:17,940
Translocation ู…ุง ุจูŠู† ูƒุฑูˆู…ูˆุณูˆู… 9 ูˆ22 ูˆุนู…ู„ CML ูˆูƒุฐุง
201
00:18:17,940 --> 00:18:24,800
CH ุฑุฃุณ CK ุฑุฃุณ ู…ุฌู…ูˆุนุฉ ุงู„ุฑุฃุณ ูˆุงู„ุฃู†ู…ูƒ ุจุฑุถู‡ ูƒู„ู‡ู…
202
00:18:24,800 --> 00:18:30,000
ุจูŠูƒูˆู†ูˆุง different types of tumor ู…ุซู„ู‹ุง
203
00:18:30,000 --> 00:18:35,080
ุงู„ุจุฑูˆุชูˆุงู†ูƒูˆุฌูŠู† ู‡ุฐู‡ ู‡ูŠ ูŠูˆู… ู…ุง ุตุงุฑ ููŠ activation ู„ู€ C
204
00:18:35,080 --> 00:18:43,020
-Myc C-A-B-L C-K ูƒูŠุฑู‡ุฒ ุงู…ุชุฒูŠุณุช ุฌูŠู†ุฒ are associated
205
00:18:43,020 --> 00:18:47,680
with Perkins lymphoma ุณูŠูˆู… ุงู„ุงู†ู„ุงู†ูƒูˆู„ ุงูˆุฑูƒูˆู„ูˆู†
206
00:18:47,680 --> 00:18:55,700
ูƒุงุฑุณูŠู†ูˆู…ุง ุจุงู„ุชุฑุชูŠุจ ุงู„ุฏุฑุงุณุงุช ุนู„ู‰ ุงู„ุญูŠูˆุงู† ุฃูŠุถู‹ุง ุฃุธู‡ุฑุช
207
00:18:55,700 --> 00:19:04,150
ุฃู† ุฃู† ููŠ ุนู„ุงู‚ุฉ ู…ุจุงุดุฑุฉ ู…ุง ุจูŠู† ุงู„ุงู†ูƒูˆุฌูŠู†ูŠูƒ ูˆูŠุฑูˆุณ ูˆู…ุง
208
00:19:04,150 --> 00:19:11,090
ุจูŠู† cross reactivity ูˆุทุจุนุง ุฃู…ุฑ ุทุจูŠุนูŠ ุฌุฏุง ู„ุฃู† ุงู„
209
00:19:11,090 --> 00:19:17,710
virus ุงู„ุงู†ูƒูˆุฌูŠู†ูŠูƒ ูˆูŠุฑูˆุณ ูŠุนู†ูŠ ุจูŠุนู…ู„ expression of
210
00:19:17,710 --> 00:19:24,190
ุงู„ antigenุงุชู‡ ุนู„ู‰ ุงู„ tumor cell ุจุบุถ ุงู„ู†ุธุฑ ุนู„ู‰ ู…ูˆู‚ุน
211
00:19:24,190 --> 00:19:28,830
ุงู„ุฎู„ุงูŠุง ุงู„ู„ูŠ ุตุงุฑ ุงู„ู„ูŠ ู„ู‡ุง tumor ุฃูˆ ู†ูˆุน ุงู„ animal
212
00:19:28,830 --> 00:19:35,240
species ูˆุฒูŠ ู…ุง ู‚ู„ู†ุง ู„ูƒู… ููŠ ุฏู„ุงุฆู„ ุฃูˆ ููŠ ุณุฌู„ุฉ ุญุงู„ุงุช
213
00:19:35,240 --> 00:19:41,600
ูƒุซูŠุฑุฉ ู…ุซุจุชุฉ ุนู„ู‰ ุนู„ุงู‚ุฉ ุงู„ู„ูŠ ู‡ูˆ ุงู„ viruses ุจุงู„ tumor
214
00:19:41,600 --> 00:19:47,200
ุฒูŠ ุงู„ Epstein-Barr Virus ุจูŠุนู…ู„ ุงู„ู„ูŠ ู‡ูˆ ุงู„ human
215
00:19:47,200 --> 00:19:51,520
T cell leukemia virus ูˆ ุงู„ human papilloma virus
216
00:19:51,520 --> 00:19:54,820
ุงู„ุฃูˆู„ุงู†ูŠ ุจูŠุนู…ู„ Perkins ูˆุงู„ุซุงู†ูŠ ุจูŠุนู…ู„ leukemia
217
00:19:54,820 --> 00:19:57,840
ูˆุงู„ุซุงู„ุซ ุจูŠุนู…ู„ cervical tumor
218
00:20:01,280 --> 00:20:06,980
ู…ุง ู‡ูŠ ุงู„ุนูˆุงู…ู„ ุงู„ุชูŠ ุชุคุซุฑ ููŠ ุงู„ incidence of cancer
219
00:20:06,980 --> 00:20:15,520
ู‚ุงู„ูˆุง ููŠ ู…ุตุทู„ุญ ุงุณู…ู‡ ุงู„ immune ุงู„ immune
220
00:20:15,520 --> 00:20:20,270
surveillance ูˆุงู„ู…ุตุทู„ุญ ู‡ุฐุง ูŠุนู†ูŠ ุฅู†ู‡ ููŠู‡
221
00:20:20,270 --> 00:20:22,990
immunological resistance against the development
222
00:20:22,990 --> 00:20:32,150
of cancer ุงู„ุฌุณู… ูŠุชุตุฏู‰ ุฅู„ู‰ ุงู„ tumor ู…ู† ุฎู„ุงู„ ุฌู‡ุงุฒ
223
00:20:32,150 --> 00:20:37,490
ุงู„ู…ุงู†ุนุฉ ูˆู…ู† ุงู„ู†ุงุณ ุงู„ู„ูŠ ู…ุง ุนู†ุฏู‡ู…ุด ู…ุงู†ุนุฉ ุนู†ุฏู‡ู…
224
00:20:37,490 --> 00:20:40,590
immunodeficiency disease usually are susceptible
225
00:20:40,590 --> 00:20:45,070
to viral infection and certain malignant neoplasm
226
00:20:52,140 --> 00:20:59,480
ุทุจุนุง ุงู„ tumor cell ุงู„ู„ูŠ ุจุชุชูƒูˆู† ุฎู„ุงู„ virus are
227
00:20:59,480 --> 00:21:04,420
sensitive to immunologic destruction ูˆู…ุน ุฐู„ูƒ ุงู„
228
00:21:04,420 --> 00:21:07,400
natural development of immunological response
229
00:21:07,400 --> 00:21:10,600
usually fail to prevent cancer from developing
230
00:21:10,600 --> 00:21:16,060
ูŠุนู†ูŠ ุตุญูŠุญ ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ุจูŠุดุชุบู„ ู„ูƒู† ูˆู…ุน ุฐู„ูƒ ุงู„ุณุฑุทุงู†
231
00:21:16,060 --> 00:21:25,020
ุฃูˆ ุงู„ tumor cell ุจุชู†ุฌุญ ููŠู‡ ููŠ ุฅู†ู‡ุง ุชู†ู…ูˆ ูˆุชุชุทูˆุฑ ูŠุนู†ูŠ
232
00:21:25,020 --> 00:21:31,320
ุจู†ุฃู…ู„ ููŠ ุงู„ู…ุณุชู‚ุจู„ ุฃู† ูŠูƒูˆู† ููŠู‡ good
233
00:21:31,320 --> 00:21:36,720
response example by vaccination with tumor antigen
234
00:21:36,720 --> 00:21:41,280
that will serve as viable option for prevention or
235
00:21:41,280 --> 00:21:47,490
treatment of cancer in the future Effect of
236
00:21:47,490 --> 00:21:50,770
Mechanism in Tumor Immunology ู…ุง ู‡ูŠ ุงู„ู…ูŠูƒุงู†ูŠุฒู…ุงุช
237
00:21:50,770 --> 00:21:55,690
ูˆุฌุฏูˆุง ุฃู†ู‡ both Adaptive ูˆ Innate Immune Response
238
00:21:55,690 --> 00:22:01,970
ุจูŠู„ุนุจูˆุง ุฏูˆุฑ ูƒุจูŠุฑ ูˆููŠ ุงู„ุนู„ุงู‚ุฉ ู…ุง ุจูŠู† ุงู„ host ูˆ ุงู„
239
00:22:01,970 --> 00:22:08,290
tumor Immune Effect of Mechanism ูˆุฌุฏุช ูˆุฌุฏูˆู‡ุง ุงู† it
240
00:22:08,290 --> 00:22:13,760
can destroy tumor cell in vitro ุจุงู„ุชุฌุฑุจุฉ ุชุชู…ุซู„ ููŠ
241
00:22:13,760 --> 00:22:18,280
ุงู„ู€ Antibody ููŠ ุงู„ู€ B-cellุŒ ุงู„ู€ NK-cellุŒ ุงู„ู€ Lact
242
00:22:18,280 --> 00:22:22,240
-cellุŒ ุงู„ู€ MacrophageุŒ ุงู„ู€ Cytokine ูƒู„ู‡ุง ุฃุจุงุฑุน ุนู†
243
00:22:22,240 --> 00:22:27,660
ู…ูŠูƒุงู†ูŠุฒู…ุงุช ุฃุซุจุชุช in vitro ุจุฅู†ู‡ุง ุจุชุฏู…ุฑ ุงู„ุฎู„ุงูŠุง
244
00:22:27,660 --> 00:22:33,860
ุงู„ุณุฑุทุงู†ูŠุฉ ูˆู‡ูŠ ุงู„ู€ Antibody ูˆ ุงู„ู€ B-cell ุนู„ู‰ ุณุจูŠู„
245
00:22:33,860 --> 00:22:36,820
ุงู„ู…ุซุงู„ ููŠ ูˆุฌูˆุฏ ูƒูˆู…ุจู„ูŠู…ู†ุช ุจุชูƒูˆู† Antibody ููŠ ูˆุฌูˆุฏ
246
00:22:36,820 --> 00:22:43,040
ูƒูˆู…ุจู„ูŠู…ู†ุช ู…ู†ุชุฌุงุช ุฃูˆ Opsonization ุงู„ุขู† ู…ูŠูƒุงู†ูŠุฒู… ู…ูู‡ูˆู…
247
00:22:43,040 --> 00:22:46,980
ุจุดูƒู„ ูƒุงู…ู„ ุชุณู„
248
00:22:46,980 --> 00:22:49,460
ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„
249
00:22:49,460 --> 00:22:53,260
ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„
250
00:22:53,260 --> 00:22:58,100
ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„
251
00:22:58,100 --> 00:23:01,720
ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„ ุชุณู„
252
00:23:01,720 --> 00:23:05,360
ุชุณู„
253
00:23:07,310 --> 00:23:14,930
ูˆูˆุฌุฏูˆู‡ุง ูƒุซูŠุฑุฉ ู‚ูˆูŠุฉ ุนู„ู‰ ุงู„ุฎู„ุงูŠุง ุงู„ู€ dispersed ุงู„ู„ูŠ
254
00:23:14,930 --> 00:23:21,030
ู‡ูŠ ุงู„ู…ู†ูุตู„ุฉ ุนู„ู‰ ุงู„ cell suspension ูˆูˆุฌุฏูˆุง ูุนุงู„ูŠุชู‡ุง
255
00:23:21,030 --> 00:23:26,890
ุฃูƒุซุฑ ุจูƒุซูŠุฑ ุนู„ู‰ ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง ุงู„ู…ู†ูุตู„ุฉ ุฃูƒุซุฑ ู…ู† ุงู„
256
00:23:26,890 --> 00:23:31,250
solid tumor ุงู„ู„ูŠ ู‡ูˆ ุจูŠูƒูˆู† ู…ุชู…ุงุณูƒ ู„ูŠุดุŸ ู„ุฃู† ุฌู‡ุงุฒ
257
00:23:31,250 --> 00:23:33,850
ุงู„ู…ู†ุงุนุฉ ูŠุณุชุทูŠุน ุฃู† ูŠุตู„ ุฅู„ู‰ ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง
258
00:23:37,530 --> 00:23:43,770
ู…ู† ุงู„ู€ Solid Tumour Cells ู†ุดูˆู ุฃูˆู„ ู…ูŠูƒุงู†ูŠุฒู… ุงู„ู„ูŠ
259
00:23:43,770 --> 00:23:49,890
ู‡ูˆ PCR Response ู„ู€ Tumour ูˆุฌุฏูˆุง ุฃู† IgPo, IgM ูˆ IgG
260
00:23:49,890 --> 00:23:55,690
Antibody ูˆุฌุฏูˆู‡ุง in vitro can kill or destroy the
261
00:23:55,690 --> 00:24:00,450
tumour cell ุทุจุนุง ููŠ ูˆุฌูˆุฏ ุงู„ complement ุทุจุนุง ู‡ุฐุง
262
00:24:00,450 --> 00:24:07,370
ุงู„ูƒู„ุงู… ุฃุซุจุชู†ุงู‡ ุจุงู„ุชุฌุฑุจุฉ in vitroุŒ ุงู„ุฏุฑุงุณุงุช ุนู„ู‰
263
00:24:07,370 --> 00:24:15,830
ุงู„ู…ุงูŠุณ ุฃูŠุถุง ุฃุซุจุชุช Indicate ุจุชุคุดุฑ ุฃูˆ ุจุชุฏู„ ุนู„ู‰ ุฃู† ุงู„
264
00:24:15,830 --> 00:24:19,350
Antitumor Antibody are effective in destroying
265
00:24:19,350 --> 00:24:25,250
some leukemia and lymphoma ูˆุทุจุนุง ุจุชู‚ู„ู„ ู…ู† ุงู„
266
00:24:25,250 --> 00:24:31,710
metastasis in several other tumors systemุŒ ุชู†ุณูˆุด
267
00:24:31,710 --> 00:24:37,780
ุฃู† ุงุญู†ุง ู‡ู†ุญูƒูŠ ุนู„ู‰ ุชุฌุงุฑุจ ุญุฏุซุช in vitro ูˆู„ูŠุณ in vivo
268
00:24:37,780 --> 00:24:43,860
ุขุฎุฑ ุญุฏุซ ุทุจุนุง ุฃุซุจุชุช ุฃู† ู‡ุฐู‡ ุงู„ุงู†ุชูŠุจุงุฏูŠ ู„ุง ุชุฃุซูŠุฑ ู„ู‡ุง
269
00:24:43,860 --> 00:24:50,500
ูˆู„ุง ุจุชู‚ุชู„ ุฎู„ุงูŠุง ุณุฑุทุงู†ูŠุฉ ู…ุงุดูŠ ุฅุฐุง ูƒุงู† ุงู„ tumor in
270
00:24:50,500 --> 00:24:55,820
solid form ูŠูˆู… ู…ุง ูŠูƒูˆู† ุงู„ tumor in solid formุŒ ุจูŠูƒุงุฒ
271
00:24:55,820 --> 00:24:58,760
ุซุงู†ูŠ destruction of tumor cell by opsonization of
272
00:24:58,760 --> 00:25:02,320
phagocytosis ูƒู„ู†ุง ุจู†ุนุฑู ุฃู†ู‡ ุงู„ุฎู„ูŠุฉ ุงู„ุบุฑูŠุจุฉ ุจู‚ู‰
273
00:25:02,320 --> 00:25:05,960
ุชูƒูˆู† ู„ู‡ุง antibody ูˆ ุจู‚ุนุฏ ุนู„ู‰ ุณุทุญ ุงู„ุฎู„ุงูŠุง ู…ุฑุงุช ูˆ
274
00:25:05,960 --> 00:25:11,240
ุจูŠุตูŠุฑ ูƒูˆู† ูˆ ุจูŠุนู…ู„ opsonization ู„ู‡ุฐู‡ ุงู„ุฎู„ูŠุฉ ุทุจุนุง
275
00:25:11,240 --> 00:25:15,240
ุชุชุนุฑู ุนู„ูŠู‡ุง ุงู„ phagocytic cell ูˆ ุจุชุฎู„ุตู†ุง ู…ู†ู‡ุงุŒ In
276
00:25:15,240 --> 00:25:23,980
vitro destruction of tumor cell ุจูˆุงุณุทุฉ Trigocytic
277
00:25:23,980 --> 00:25:28,780
cell ุฃุตู„ุง ู‚ุชู„
278
00:25:28,780 --> 00:25:32,900
ุฃูˆ ุนู…ู„ destruction ู„ู„ tumor cell ููŠ ูˆุฌูˆุฏ ุงู„ ant
279
00:25:32,900 --> 00:25:39,360
tumor ุงู„ู„ูŠ ู‡ูˆ immune serum and complementุŒ ู…ูŠูƒุงู†ูŠุฒู…
280
00:25:39,360 --> 00:25:43,220
ุซุงู„ุซ Antibody-mediated loss of adhesion properties
281
00:25:43,220 --> 00:25:52,080
of tumor cellุŒ ุงู„ู€ Adhesion Molecule ู„ุงุฒู… ุชุชุญู„ู„
282
00:25:52,080 --> 00:25:56,540
ุนุดุงู† ูŠุตูŠุฑ ููŠู‡ ู…ุชุงุณุชุงุณูŠุณ
283
00:25:56,540 --> 00:26:01,300
ู…ุชุงุณุชุงุณูŠุณ ุงูƒุชููŠุฉ ู…ุฎุชู„ูุฉ ุนู† ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚
284
00:26:01,300 --> 00:26:06,240
ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚ ู…ุฎู„ูˆู‚
285
00:26:10,100 --> 00:26:15,140
ุนุดุงู† ุชุฑุชุจุท ุจุฎู„ุงูŠุง ุฃูˆ ุจุงู†ุณุฌุฉ ุฃุฎุฑู‰ ู…ูˆุฌูˆุฏุฉ ููŠ ุฃู…ุงูƒู†
286
00:26:15,140 --> 00:26:19,300
ุฃุฎุฑู‰ ูˆุจุงู„ุชุงู„ูŠ ุจูŠุญุตู„ ููŠู‡ metastasisุŒ ุงู„ antibody
287
00:26:19,300 --> 00:26:24,220
ุงู„ู…ูˆุฌู‡ุฉ ุถุฏ ู‡ุฐู‡ ุงู„ู€ tumor cell surfaces can
288
00:26:24,220 --> 00:26:28,080
interfere with the adhesive properties ูˆู‡ุฐุง ุงู„ูƒู„ุงู…
289
00:26:28,080 --> 00:26:33,200
ุฃูŠุถุง done in vitro cell mediated responses
290
00:26:33,200 --> 00:26:38,100
destruction by cytotoxic T lymphocytes ุฃูŠุถุง
291
00:26:38,100 --> 00:26:44,150
ุฃุซุจุชู†ุงู‡ุง in vitroุŒ ู‡ูŠ ู…ุณุคูˆู„ุฉ ุนู† ู‡ุฐู‡ ุงู„ุฎู„ุงูŠุง ูˆู…ุณุคูˆู„ุฉ
292
00:26:44,150 --> 00:26:52,830
ุนู† ุฅุฏุงุฑุฉ ุชู…ุฑ ุณู„ ุจูˆุฑูŠุง ููŠ ุงู„ูˆุงู‚ุนุŒ ุทุจุนุง ุงู„ู€ Antibody
293
00:26:52,830 --> 00:26:55,890
Dependent Cell Mediated Cytotoxicity ุฏูŠ ุนุจุงุฑุฉ ุนู†
294
00:26:55,890 --> 00:27:01,870
ู…ูŠูƒุงู†ูŠุฒู… ุจุชู…ู† ุฎู„ุงู„ ุงุฑุชุจุงุท ุงู„ .. ุงู„ .. ุงู„ .. ุงู„ ..
295
00:27:01,870 --> 00:27:06,090
Phagocytic Cell ุจุงู„ Fc Portion of Antibody ุงู„ู„ูŠ
296
00:27:06,090 --> 00:27:09,670
ุฌุงู„ุณ ุนู„ู‰ ุณุทุญ ุงู„ุฎู„ูŠุฉ ุงู„ุณุฑุทุงู†ูŠุฉุŒ ุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠ
297
00:27:09,670 --> 00:27:14,510
cell to cell contact ูˆ ุจูŠุตูŠุฑ ููŠ releasing ู„ ุงู„
298
00:27:14,510 --> 00:27:20,050
substance which can kill the tumor cellุŒ ุงุณุชุฑูƒุดู† of
299
00:27:20,050 --> 00:27:31,790
tumors by NK or NKT or ู„ุฃูƒุณู„ ุงู„ุชู„ุงุชุฉ ู…ุงุดูŠุŒ ู„ุง ุนู„ุงู‚ุฉ
300
00:27:31,790 --> 00:27:35,650
ุทุจุนุง ูƒู†ุง ุจู†ุนุฑู ุฃู†ู‡ ุฎู„ุงุต ุฃู† ุงู„ุงู†ูƒุณู„ ุชุชุญุณุณ ุงู„ู„ูŠ ู‡ูˆ
301
00:27:38,140 --> 00:27:42,000
ู…ูˆู„ูŠูƒูŠูˆู„ ุนู„ู‰ ุณุทุญ ุงู„ุฎู„ุงูŠุง ุชูŠูˆู…ุฑ ุณูŠู„ ุบุงู„ุจุง ุชุนู…ู„
302
00:27:42,000 --> 00:27:46,620
shading ุชุนู…ู„ masking ู„ ุงู„ู„ูŠ ู‡ูˆ ุงู„ MSC ู…ูˆู„ูŠูƒูŠูˆู„
303
00:27:46,620 --> 00:27:52,520
ูˆุจุงู„ุชุงู„ูŠ ุชุชุนุฑู ุนู„ูŠู‡ุง ุงู„ู„ูŠ ู‡ูˆ ุงู„ุงู†ูƒุณู„ุŒ ุฃูŠุถุง ุงู„ุงู†ูƒุณู„
304
00:27:52,520 --> 00:27:56,960
have receptor ู„ู„ FC portion of IGG ูˆุจุงู„ุชุงู„ูŠ ู…ู†
305
00:27:56,960 --> 00:28:04,500
ุฎู„ุงู„ ADCC ู…ู…ูƒู† ุชุชุฎู„ุต ู…ู† ุงู„ tumor cellุŒ ุจู…ุฌุฑุฏ ู…ุง
306
00:28:04,500 --> 00:28:07,680
ุชุฑุชุจุท ุจุชูุฑุฒ ุงู„ tumor ู„ุฅู† ูƒูŠ cell tumor necrosis
307
00:28:07,680 --> 00:28:13,120
factor ฮฑ ูˆ ุงู„ู„ูŠ ุจูŠุนู…ู„ู‡ู… ูˆุฑุฌูˆ tumor necrosis ุงู„ lag
308
00:28:13,120 --> 00:28:18,820
ุฃูŠุถุง ู‡ูŠ ุนุจุงุฑุฉ ุนู† tumor specific killer cells ูˆ
309
00:28:18,820 --> 00:28:22,660
ู…ู…ูƒู† ู†ุณุชู†ุจุทู‡ุง ุฃูˆ ู†ุงุฎุฏู‡ุง ู…ู† ุจุนุถ ุงู„ู…ุฑุถู‰ ุงู„ู„ูŠ ุนู†ุฏู‡ู…
310
00:28:22,660 --> 00:28:29,400
tumorุŒ ุจู†ู…ูŠู‡ุง ุจุฑุง ููŠ ูˆุฌูˆุฏ IL-2 ูˆู†ุฑุฌุนู‡ุง ุซุงู†ูŠ ู„ู„ู…ุฑูŠุถ
311
00:28:29,400 --> 00:28:36,920
ู†ูุณู‡ุŒ ู‡ุฏูˆู„ุฉ ุจู†ุดุทู‡ ุงู„ู„ูŠ ู‡ูˆ ุงู„ู€ mechanism ุงู„ู„ูŠ ุจู†ุญูƒูŠ
312
00:28:36,920 --> 00:28:40,580
ุนู†ู‡ ุณูˆุงุก ูƒุงู† ADCC ุงูˆ Direct Killing By Ankyl Cell
313
00:28:40,580 --> 00:28:43,600
Destruction
314
00:28:43,600 --> 00:28:46,300
of tumor cell by activated macrophage and
315
00:28:46,300 --> 00:28:50,800
neutrophilุŒ ุทุจุนุง ูƒู„ู†ุง ุจู†ุนุฑู ุฃู† ุงู„ macrophage ุจุชุชู†ุดุท
316
00:28:51,320 --> 00:28:57,540
by releasing gamma interferonุŒ ุงู„ุชุดุชุช ู…ู† ุฎู„ุงู„ TCD4
317
00:28:57,540 --> 00:29:08,620
lymphocytesุŒ ูˆุทุจุนุง ุงู„ gamma interferon ู„ู‡ tumor
318
00:29:08,620 --> 00:29:15,280
specificุŒ ุจูŠุณุชุฎุฏู…
319
00:29:15,280 --> 00:29:16,480
ูƒ cytotoxic
320
00:29:20,430 --> 00:29:26,630
Cytokine against tumor cellุŒ ุฃูŠุถุง ุจุฅุทู„ุงู‚ ู„ุงุฒูˆุฒุงูŠู…
321
00:29:26,630 --> 00:29:30,730
ูˆู†ูƒุฑูˆุณ ูุงูƒุชูˆุฑู‡ ุงู„ูุง ุจูŠู‚ุชู„ูˆุง tumor cell
322
00:29:35,370 --> 00:29:38,730
ุฃู…ุง ุชุนู…ู„ Inhibition ุฃูˆ ุชุนู…ู„ Growth ู„ู€Premarignant
323
00:29:38,730 --> 00:29:44,050
ูˆTumorignant CellุŒ ุทุจุนุงู‹ ู†ุนุฑู ุฃู†ู‡ ููŠู‡ Cytokine
324
00:29:44,050 --> 00:29:47,650
Inhibitor ูˆCytokine ูˆููŠู‡ Stimulatory Transformed
325
00:29:47,650 --> 00:29:51,350
Growth Factor BetaุŒ ูˆุงุญุฏ ู…ู† ุงู„ู€Cytokine ุงู„ู„ูŠ ุจูŠุนู…ู„
326
00:29:51,350 --> 00:29:56,990
Inhibition ู„ู„ immune response ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠู‡
327
00:29:56,990 --> 00:30:04,460
promotion ู„ู„ tumor growth ููŠ ู‡ุฐู‡ ุงู„ุญุงู„ุฉ ูˆ ุจูŠุงู„ูˆ
328
00:30:04,460 --> 00:30:08,980
ุงู†ุฌูŠูˆุฌูŠู†ูŠูƒ ุจู…ุนู†ู‰
329
00:30:08,980 --> 00:30:16,720
ุฃู†ู‡ ุจูŠุณู‡ู„ ููŠ ุนู…ู„ูŠุฉ ู†ู…ูˆ ุงู„ูƒุงู†ุณุฑ ู…ู† ุฎู„ุงู„ ุงู„ู„ูŠ ู‡ูˆ
330
00:30:16,720 --> 00:30:23,120
ุชูƒูˆูŠู† ุงู„ุงู†ุฌูŠูˆุฌูŠู†ูŠุณูŠ ุงู„ู„ูŠ ู‡ูˆ blood vessels to the
331
00:30:23,120 --> 00:30:25,360
tumor cell
332
00:30:27,510 --> 00:30:32,910
Tumor Microsfactory ูˆ Interferon ุฌุนู…ุง ุฃูŠุถุง ู„ู‡ู…
333
00:30:32,910 --> 00:30:37,770
Anti-Tumor Effect ู„ูŠุดุŸ ู„ุฃู†ู‡ู… ุจูŠุนู…ู„ูˆุง Upregulation
334
00:30:37,770 --> 00:30:44,190
ู„ู„ MSC Class 1 ูˆ2 ูˆุจุงู„ุชุงู„ูŠ ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ ูŠุชุนุฑู ุนู„ูŠู‡ู…
335
00:30:44,190 --> 00:30:48,590
ุจุณู‡ูˆู„ุฉุŒ ูŠูˆู… ู…ุง ูŠุญุตู„ ููŠู‡ Decrease expression ู„ู„MSC
336
00:30:48,590 --> 00:30:54,770
Determinants ุนู„ู‰ ุณุทุญ ุงู„ tumor cell ุจูŠูƒูˆู† ูˆุณูŠู„ุฉ ู…ู†
337
00:30:54,770 --> 00:30:59,450
ูˆุณุงุฆู„ ุชู‡ุฑุจ ุงู„ุฎู„ูŠุฉ ุงู„ุณุฑุทุงู†ูŠุฉ from the action of
338
00:30:59,450 --> 00:31:05,450
cytokine transfection
339
00:31:05,450 --> 00:31:12,470
of tumor cell with genes coding for cytokine ุฒูŠ IL
340
00:31:12,470 --> 00:31:21,430
-117 ูˆู‚ุงู… ุงู†ุชุฑููŠุฑูˆู† ู…ุงุดูŠุŒ ูˆุจุนุฏ ุฐู„ูƒ ุฑุฌุนู‡ู… ู…ุงุดูŠ
341
00:31:21,430 --> 00:31:22,290
ู„ู„ู…ุฑูŠุถ
342
00:31:25,210 --> 00:31:32,150
ุฃูˆู„ู‰ ุงู„ tumor-pairing mice ุฃุธู‡ุฑุช ู†ุชุงุฆุฌ ุฌูŠุฏุฉ ููŠ
343
00:31:32,150 --> 00:31:38,150
ุงู„ู€ inhibition of growth of tumorุŒ ุทูŠุจุŒ
344
00:31:38,150 --> 00:31:43,430
ุฅูŠุด ุงู„ู€ limitation of effectiveness of immune
345
00:31:43,430 --> 00:31:47,090
response against tumorุŸ ูƒู„ู†ุง ุจู†ุนุฑู ุฃู†ู‡ ู…ุน ูˆุฌูˆุฏ
346
00:31:47,090 --> 00:31:54,710
immune response ู„ุฃู† tumor cell ุฃูˆ tumor can growุŒ ูˆ
347
00:31:54,710 --> 00:32:02,310
ุจูŠุชุบู„ุจ ุนู„ู‰ ุงู„ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนูŠุŒ ู„ูŠุด ู†ุดูˆู ุฃูŠูˆุฉ there is no
348
00:32:02,310 --> 00:32:05,430
question ุฃู† ููŠ ูˆุฌูˆุฏ ุงู„ immune responseุŒ ุงู„ immune
349
00:32:05,430 --> 00:32:13,050
response ุจูŠูƒูˆู† ุดุบุงู„ ููŠ ูˆุฌูˆุฏ ุงู„ tumor ู„ูƒู† ุจุงู„ุฑุบู…
350
00:32:13,050 --> 00:32:20,350
ู…ู† ุฐู„ูƒ ุงู„ tumor continue to growุŒ ูˆุทุจุนุง ุฏุฑุณูˆุง ุนุฏุฉ
351
00:32:20,350 --> 00:32:21,330
ู…ูŠูƒุงู†ูŠุฒู…ุงุช
352
00:32:23,960 --> 00:32:35,180
ุทุจุนุง ู‡ุฐู‡ ุจุชุชุนู„ู‚ ุจุงู„ tumor cell ุฃูˆ ุจ tumor and host
353
00:32:35,180 --> 00:32:38,380
relationship
354
00:32:38,380 --> 00:32:44,360
ู†ุดูˆู ุงู„ู…ูŠูƒุงู†ูŠุฒู…ุงุช ุงู„ู„ูŠ ุจุชุชุนู„ู‚ ุจุงู„ tumorุŒ ูŠู‚ูˆู„ ุฅู† ู…ู†
355
00:32:44,360 --> 00:32:47,540
ูˆุงุญุฏ failure of tumor to provide suitable target
356
00:32:47,540 --> 00:32:52,040
ูŠุนู†ูŠ ูƒูŠู ุชุชุนุฑู ูŠุชุนุฑู ุนู„ูŠู‡ุง ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉุŒ ุจุฏู‡ ูŠูƒูˆู†
357
00:32:52,040 --> 00:32:56,060
ููŠู‡ targetุŒ ุจุฏู‡ ูŠูƒูˆู† ููŠู‡ antigenุŒ ู†ุดูˆู ุงู„ูˆุณุงุฆู„ ุงู„ุชูŠ
358
00:32:56,060 --> 00:33:01,640
ุชุชู‡ุฑุจ ู…ู† ุฎู„ุงู„ู‡ุง ุงู„ tumor cell from the immune
359
00:33:01,640 --> 00:33:06,020
responseุŒ ูŠู‚ูˆู„ ุฅู† ู…ู† ูˆุงุญุฏุŒ ุชุงูƒูˆุจ antigen ูƒูŠุจุชู‡ ุจุชุทูŠุน
360
00:33:06,020 --> 00:33:10,050
ูƒู„ ุงู„ antigenุงุช ุงู„ู„ูŠ ุนู„ู‰ ุณุทุญู‡ุง ูˆุจุงู„ุชุงู„ูŠ ูƒู„ ุงู„ tumor
361
00:33:10,050 --> 00:33:13,550
ุงู†ุชูŠุฌูŠู† ู…ุด ู…ูˆุฌูˆุฏุฉุŒ ููƒูŠุจุฑูŠ ุงุชุนุฑู ุนู„ูŠู‡ุง ุฌุฒุก ู…ู†ู‡ุงุŒ ู†ู…ุฑ
362
00:33:13,550 --> 00:33:16,770
ุงุชู†ูŠู† lack of a C class one moleculeุŒ ุทุจ ู…ุง ู‡ูˆ ุฏูŠ
363
00:33:16,770 --> 00:33:21,970
ุนุจุงุฑุฉ ุนู† presenting molecule ู„ู„ุงู†ุชูŠุฌูŠู†ุŒ deficient
364
00:33:21,970 --> 00:33:25,510
of antigen processingุŒ ุฃุตู„ุง ู…ุงููŠุด ุงู†ุชูŠุฌูŠู† ุนุดุงู†
365
00:33:25,510 --> 00:33:29,770
ู†ุนู…ู„ู‡ processingุŒ antigenic modulation ุจูŠุบูŠุฑ ุงู„ุฌู‡ุงุฒ
366
00:33:29,770 --> 00:33:36,270
ุงู„ุฎู„ูŠุฉ ุงู„ุณุฑุทุงู†ูŠุฉ ููŠ ุงู„ุงู†ุชูŠุฌูŠู† ุจุงุณุชู…ุฑุงุฑุŒ ูุจุงู„ุชุงู„ูŠ
367
00:33:36,270 --> 00:33:41,000
ุจูŠุตูŠุฑ ููŠ ุงูŠู‡ุŸ ุฎู„ู„ ููŠ ุงู„ุชุนุฑู ุนู„ูŠู‡ุŒ antigenic masking
368
00:33:41,000 --> 00:33:46,740
of the tumorุŒ ูŠูˆู… ูŠุบุทูŠ ุงู„ุงู†ุชูŠุฌูŠู† ูƒูˆุฑูˆู†ุง ุงู„ุฎู„ูŠุฉ
369
00:33:46,740 --> 00:33:51,420
ุงู„ุณุฑุทุงู†ูŠุฉ ุจุฑุถู‡ ู„ุงุชุณุชุทูŠุน ุฃู† ุชุชุนุฑู ุนู„ูŠู‡ุงุŒ resistance
370
00:33:51,420 --> 00:33:55,260
of tumor cell to tumor seedal effector pathwayุŒ ุจุนุฏ
371
00:33:55,260 --> 00:34:01,540
ุงู„ุฎู„ูŠุฉ ุงู„ุณุฑุทุงู†ูŠุฉ ุจุชู‚ุงูˆู… any ุงู„ู„ูŠ ู‡ูˆ tumor seedal
372
00:34:01,540 --> 00:34:02,620
effector pathway
373
00:34:05,230 --> 00:34:10,050
ูุงู„ู†ูˆุน ุงู„ุซุงู†ูŠ ุฃูˆ ุงู„ุนุงู…ู„ ุงู„ุซุงู†ูŠ failure of tumor to
374
00:34:10,050 --> 00:34:18,910
induce ineffective immune responseุŒ ุทุจุนุง ุฒูŠ ู…ุง
375
00:34:18,910 --> 00:34:29,170
ู‚ู„ู†ุง ุจูŠุตูŠุฑ ููŠู‡ ูุดู„ ููŠ ุงู„ู„ูŠ ู‡ูˆ ุชูƒูˆูŠู† ุงู„ immune
376
00:34:29,170 --> 00:34:29,890
response
377
00:34:32,510 --> 00:34:36,530
ูˆุทุจุนุง ูˆุฌูˆุฏ ุงู„ู€ tumor ูŠุนู†ูŠ ุฃู†ู‡ ู„ุงุฒู… ูŠุตูŠุฑ ููŠู‡
378
00:34:36,530 --> 00:34:40,450
response ุจุนุถ ุงู„ู…ุฑุงุช ุจูŠูุดู„ ุงู„ู€ tumor ููŠ ุชุญู‚ูŠู‚ ู‡ุฐู‡
379
00:34:40,450 --> 00:34:43,930
ุงู„ุธุงู‡ุฑุฉ ุจุณุจุจ ููŠ ุฐู„ูƒ lack of antigenic epitopes
380
00:34:43,930 --> 00:34:48,770
ู…ุงููŠุด epitopes ู†ู…ุฑุฉ ุงุซู†ูŠู† decrease MSC or tumor
381
00:34:48,770 --> 00:34:52,970
antigen expression ู†ู…ุฑุฉ ุซู„ุงุซุฉ ู…ุงููŠุด costimulatory
382
00:34:52,970 --> 00:34:56,570
signal ู†ู…ุฑุฉ ุฃุฑุจุนุฉ production of inhibitory
383
00:34:56,570 --> 00:35:02,390
substance ู‡ูŠ ุจุนุถ ุงู„ุตูŠุชุฑูƒุงูŠู† ุงู„ู„ูŠ ู‡ู†ุดูˆูู‡ุง ู†ู…ุฑุฉ ุฎู…ุณุฉ
384
00:35:02,390 --> 00:35:07,230
shedding of tumor antigen in the surrounding area
385
00:35:07,230 --> 00:35:10,690
ุฃูˆ in the blood ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ ููŠ tolerance ู„ู„ู€
386
00:35:10,690 --> 00:35:18,250
antigen ููŠ ุงู„ุฌุณู… ู†ู…ุฑุฉ ุณุชุฉ ุงู„ู„ูŠ ู‡ูˆ induction of T
387
00:35:18,250 --> 00:35:24,550
cell signaling defect by tumor burden ู…ุงููŠุด cell
388
00:35:24,550 --> 00:35:32,170
signal ุทูŠุจ ู‡ุฐุง ู…ุง ูŠุชุนู„ู‚ ุจุงู„ู€ tumor ู†ุดูˆู ู…ุง ูŠุชุนู„ู‚ ุจุฅูŠุด
389
00:35:32,170 --> 00:35:35,050
ุจุงู„ู€ host
390
00:35:46,230 --> 00:35:50,450
failure of the host to respond to antigenic tumor
391
00:35:50,450 --> 00:35:54,430
ู‚ุงู„ูˆุง ุจุนุฏ ู…ุฑุงุช ุจูŠูƒูˆู† ููŠู‡ neuro suppression or
392
00:35:54,430 --> 00:36:01,530
deficiency of the host ุจุฅุดูŠ ุจุชุดู…ู„ apoptosis ูˆ
393
00:36:01,530 --> 00:36:05,810
signaling defect of the T cell ูˆุงู„ุณุจุจ ููŠ ุฐู„ูƒ ูˆุฌูˆุฏ
394
00:36:05,810 --> 00:36:08,470
carcinogenic agent ูˆุฅู† ูƒุงู† physical or chemical
395
00:36:08,470 --> 00:36:15,410
agent or infection or even age ุขู‡ ูŠุนู†ูŠ ุงู„ู†ุงุณ
396
00:36:15,410 --> 00:36:19,030
ุงู„ุงุฎุชูŠุงุฑูŠุฉ ูƒู…ุงู† ู…ู…ูƒู† ู…ุง ู†ุดูˆู ู†ู…ุฑุฉ ุงุซู†ูŠู† deficient
397
00:36:19,030 --> 00:36:22,170
presentation of tumor antigen ู…ุงููŠ by the host
398
00:36:22,170 --> 00:36:24,530
antigen presenting cell ู…ุง ู‚ุฏุฑุช ุงู„ู€ antigen
399
00:36:24,530 --> 00:36:28,430
presenting cell ุงู„ู„ูŠ ู‡ูˆ ุชุนู…ู„ antigen presentation
400
00:36:28,430 --> 00:36:33,070
ู„ู„ู€ tumor antigen ุงู„ู†ู…ุฑุฉ ุซู„ุงุซุฉ failure of host
401
00:36:33,070 --> 00:36:37,970
effector to reach tumor ุจุนุถ ุงู„ู…ุฑุงุช ุจูŠูƒูˆู† ุงู„ู€ tumor
402
00:36:37,970 --> 00:36:41,790
ู…ุชุฎุจูŠ ููŠ ุฃู…ุงูƒู† ู„ุง ูŠุณุชุทูŠุน ุฃู† ุชุตู„ ุฅู„ูŠู‡ุง ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนุฉ
403
00:36:41,790 --> 00:36:47,640
ุฒูŠ ุงู„ู€ stromer carrier ู…ุฑุฉ ุฎู…ุณุฉ host failure of host
404
00:36:47,640 --> 00:36:54,420
to kill variant tumor cell because of dominant
405
00:36:54,420 --> 00:36:58,760
immunodominant antigen on parental tumor cell ุทุจุนุง
406
00:36:58,760 --> 00:37:05,100
ุจูŠูƒูˆู† ุงู„ู€ antigen ููŠ ู‡ุฐู‡ ุงู„ุญุงู„ุฉ dominant
407
00:37:05,100 --> 00:37:15,530
antigen ุนู„ู‰ ุงู„ู€ parental ุงู„ู„ูŠ ู‡ูˆ tumor cell
408
00:37:15,530 --> 00:37:22,610
immunodiagnosis
409
00:37:22,610 --> 00:37:27,750
ู„ูŠุด ุจุฏู†ุง ู†ุนู…ู„ immunodiagnosis ู‚ุงู„ูˆุง ู„ู‡ ู‡ุฏููŠู† ู†ู…ุฑุง
410
00:37:27,750 --> 00:37:31,090
ูˆุงุญุฏ to detect antigen specific to tumor and cell
411
00:37:31,090 --> 00:37:37,670
ู†ู…ุฑุง ุงุซู†ูŠู† ู„ุชู‚ูŠูŠู…
412
00:37:37,670 --> 00:37:42,000
lost immune response to the tumor ุทุจุนุง ุงู„ู€ tumor
413
00:37:42,000 --> 00:37:46,220
cell ุจูŠ express cytoplasmic ุฃูˆ cell surface ุฃูˆ
414
00:37:46,220 --> 00:37:50,100
secreted product that are different in nature and
415
00:37:50,100 --> 00:37:53,340
or quantity from those produced by their normal
416
00:37:53,340 --> 00:37:56,800
counterpart ุทุจูŠุนูŠ ุฌุฏุง tumor cell ุญุชู‰ ุชูุฑุฒ ู‡ุฐู‡
417
00:37:56,800 --> 00:37:59,720
ุงู„ุญุงุฌุงุช ุณูˆุงุก ูƒุงู†ุช cytoplasmic ุฃูˆ ุนู„ู‰ ุงู„ู€ cell
418
00:37:59,720 --> 00:38:05,040
surface ุฃูˆ ููŠ secreted product ุจุชุฎุชู„ู ุงุฎุชู„ุงู ูƒู„ู‡
419
00:38:05,040 --> 00:38:11,510
ุนู† ุงู„ู€ normal counterpart ุจุณุจุจ ุนุฏุฏ ุงู„ุงู†ุชุฌูŠู†ูŠุงุช
420
00:38:11,510 --> 00:38:13,850
ุงู„ุตุญูŠุญุฉ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ
421
00:38:13,850 --> 00:38:19,490
ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚
422
00:38:19,490 --> 00:38:22,970
ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ
423
00:38:22,970 --> 00:38:23,110
ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ
424
00:38:23,110 --> 00:38:23,130
ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚
425
00:38:23,130 --> 00:38:23,310
ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ
426
00:38:23,310 --> 00:38:37,910
ู„ู„ู…ุฑู‚ ุงู„ุตุญูŠุญ ู„ู„ู…ุฑู‚ ุงู„ุตุญ
427
00:38:38,340 --> 00:38:42,300
ูˆุญุตู„ู†ุง ุนู„ู‰ ู…ูˆู†ูˆูƒู„ูˆู†ุงู„ ุงู„ุงู†ุชูŠุจุงุฏูŠ ู‡ุฐู‡ ุงู„ุงู†ุชูŠุจุงุฏูŠ
428
00:38:42,300 --> 00:38:46,320
ู†ุณุชุฎุฏู…ู‡ุง ูƒุฃู…ูŠ ุจูŠุณู…ูˆู‡ุง immunodiagnostic antibody
429
00:38:46,320 --> 00:38:50,840
for immunodiagnosis of a human tumor and their
430
00:38:50,840 --> 00:38:58,700
products these are widely used as reliable
431
00:38:58,700 --> 00:39:05,660
immunodiagnostic procedure ูˆู†ุดูˆู ุงู„ุฃู…ุซู„ุฉ ุนู„ู‰ ุฐู„ูƒ
432
00:39:06,870 --> 00:39:10,470
ู‚ุงู„ูˆุง detection of myeloma protein produced by
433
00:39:10,470 --> 00:39:14,570
plasma cell tumor ุทุจุนุง ููŠ ุงู„ู€ multiple myeloma ูƒู†ุง
434
00:39:14,570 --> 00:39:18,690
ุจู†ุนุฑู ุฃู†ู‡ ููŠ antibody ุจุชุชูƒูˆู† ู…ู† plasma cell ููŠ ู‡ุฐู‡
435
00:39:18,690 --> 00:39:22,990
ุงู„ุญุงู„ุฉ ูˆุจุงู„ุชุงู„ูŠ detection of these proteins or
436
00:39:22,990 --> 00:39:28,430
antibody can be diagnostic ุทุจุนุง ู…ุซุงู„ ุขุฎุฑ ููŠ
437
00:39:28,430 --> 00:39:30,410
multiple myeloma ุฃูŠุถุง ููŠ light chain
438
00:39:30,410 --> 00:39:34,230
immunoglobulin ู†ุดูˆูู‡ุง ููŠ ุงู„ู€ pensions protein ููŠ ุงู„ู€
439
00:39:34,230 --> 00:39:37,430
urine ู‡ุฐุง ุนุจุงุฑุฉ ุนู† Diagnostic Criteria ุฃูŠุถู‹ุง
440
00:39:37,430 --> 00:39:42,450
Indication ุนู„ู‰ Plasma Cell Tumor ุฃู…ุง ุงุซู†ูŠู†
441
00:39:42,450 --> 00:39:45,450
Detection ูˆ Alpha-Feto Protein ูƒู„ ู…ู† ูŠุนุฑู ุฃู† ุงู„ู€
442
00:39:45,450 --> 00:39:48,630
Alpha-Feto Protein ู‡ูˆ ุนุจุงุฑุฉ ุนู† ุจุฑูˆุชูŠู† ู…ูˆุฌูˆุฏ ููŠ ุงู„ู€
443
00:39:48,630 --> 00:39:53,650
Fetal Serum ูˆู‡ูŠ ุจุงู„ุชุงู„ูŠ ุจุนุฏ ูˆู„ุงุฏุฉ ุงู„ู€ level ุจูŠูƒูˆู†
444
00:39:53,650 --> 00:39:59,670
ุนุงู„ูŠ ู„ูƒู† ุจูŠุจุฏุฃ ูŠู†ุฒู„ ุจุณุฑุนุฉ ู„ุบุงูŠุฉ ุนุดุฑูŠู† ู†ุงู†ูˆ ุฌุฑุงู…
445
00:39:59,670 --> 00:40:05,450
ุจูŠุฑู…ูŠู„ ุทุจุนุง ููŠ ุฃูƒุซุฑ ู…ู† ููŠ ุญุงู„ุงุช ู…ุฑุถูŠุฉ ุฒูŠ ุงู„ู€
446
00:40:05,450 --> 00:40:10,370
ovarian and testicular embryonal a non cancerous
447
00:40:10,370 --> 00:40:15,410
hepatic disorder ู‡ุฐุง ุงู„ู€ level of alpha-fetoprotein
448
00:40:15,410 --> 00:40:23,170
ุจูŠุฒูŠุฏ ู‚ุงู„ูˆุง ุฅุฐุง ุฒุงุฏ ูˆุตู„ ุฎู…ุณู…ูŠุฉ ู„ุฃู„ู ู†ุงู†ูˆ ุฌุฑุงู…
449
00:40:23,170 --> 00:40:29,620
ุจูŠุฑู…ูŠู„ ู‡ุฐุง ุจูŠุนู†ูŠ ุนู„ู‰ ุฃู† ููŠ tumor ุจูŠู†ุชุฌ Alpha
450
00:40:29,620 --> 00:40:35,480
-Fetoprotein ูˆู…ุชุงุจุนุฉ ุงู„ู€ Alpha-Fetoprotein ุจูŠุนุฑูู†ุง
451
00:40:35,480 --> 00:40:41,080
ุฅุฐุง ูƒุงู† ุงู„ู€ tumor ุจุณู„ูˆ ุฑูŠุฌู„ุดู† ุฃูˆ ุฑูŠุจุฑูˆู„ุฌุดู† CAA
452
00:40:41,080 --> 00:40:44,920
ุงุญู†ุง ู‚ู„ู†ุงู‡ุง ุฏู‡ ุนุจุงุฑุฉ ุนู† ุงู„ู€ glycorrotine ููŠ ุงู„ูˆุถุน
453
00:40:44,920 --> 00:40:50,640
ุงู„ุทุจูŠุนูŠ ุจูŠู†ุชุฌ by gastrointestinal tract ูˆุฎุตูˆุตุง ุงู„ู€
454
00:40:50,640 --> 00:40:56,550
colon ูˆูŠูˆู… ูŠุตูŠุฑ ุงู„ุฎู„ุงูŠุง ุณุฑุทุงู†ูŠุฉ ุงู„ู€ CA ูŠุชู… ุฅุทู„ุงู‚ู‡ุง
455
00:40:56,550 --> 00:41:03,350
ููŠ ุงู„ุฏู… ุฅุฐุง ุฒุงุฏุช ุงู„ุชุฑูƒูŠุฒ ุนู„ู‰ 2.5 ู†ุงู†ูˆ ุฌุฑุงู… ุจูŠุฑู…ูŠู„
456
00:41:03,350 --> 00:41:08,230
ุจูŠุนู†ูŠ ููŠ ู…ุงู„ูƒ ู†ุงู†ุณูŠ ุทุจุนุง ุงู„ู€ high level ูƒู…ุงู† ูˆุฌุฏูˆู‡
457
00:41:08,230 --> 00:41:13,290
ููŠ non cancerous disease
458
00:41:13,290 --> 00:41:17,690
ุฒูŠ ุณูŠุฑูˆุณุฒ ูˆ ุงู„ู€ inflammatory disease of the
459
00:41:17,690 --> 00:41:19,410
intestinal tract and lung
460
00:41:23,990 --> 00:41:30,070
PCSA ุจุฑุงู†ุฌ ู„ุงูŠูƒูˆู„ูˆุซูŠู† ู…ูˆุฌูˆุฏ ููŠ ุงู„ู€ ductal
461
00:41:30,070 --> 00:41:36,330
epithelial cells of the prostate ุฅุฐุง ูƒุงู† ุชุฑูƒูŠุฒ ุจู€
462
00:41:36,330 --> 00:41:40,030
8 ุฅู„ู‰ 10 ู†ุงู†ูˆ ุฌุฑุงู… ููŠ ุงู„ุจู„ุฏ ุจูŠุนู†ูŠ ุฃู†ู‡ ููŠู‡ prostate
463
00:41:40,030 --> 00:41:48,250
cancer ุงู„ู€ cancer antigen 125 CA125
464
00:41:50,660 --> 00:41:56,280
ุทุจุนุง ู‡ุฐุง ุจุฑุนุงู† tumor marker ูŠุณุชุฎุฏู… for monitoring
465
00:41:56,280 --> 00:42:01,880
the therapy of ovarian cancer C125
466
00:42:01,880 --> 00:42:06,760
ุฃูŠุถุง ุจูŠุฒูŠุฏ during peritoneal inflammatory process
467
00:42:06,760 --> 00:42:10,600
ููŠู‡ other marker ู‡ูˆ ุจุฑุนุงู† pan marker ุจูŠุณู…ูˆ pan
468
00:42:10,600 --> 00:42:17,410
carcinoma marker ุงู„ู„ูŠ ู‡ูˆ P72.3 ู‡ูˆ ุจุฑุนุงู† Monoclonal
469
00:42:17,410 --> 00:42:23,730
Antibody That Recognize All Carcinoma In Human ู‡ูˆ
470
00:42:23,730 --> 00:42:27,710
ุจุฑุนุงู† Monoclonal Antibody ุงุณุชุฎุฏู…ูˆุง ู„ูŠู‡ ุงู„ุชุนุฑู ุนู„ู‰
471
00:42:27,710 --> 00:42:34,250
ูƒู„ ุฃู†ูˆุงุน ุงู„ูƒุงุฑุณูŠู†ูˆู…ุง ููŠ ุงู„ุฌุณู… ู…ู† ุงู„ุณุจุจ ุจูŠุณุชุฎุฏู…ูˆุง
472
00:42:34,250 --> 00:42:37,570
ุทุจุนุง numerous attempts have been made to treat
473
00:42:37,570 --> 00:42:41,730
cancer in animal and human by immunological means
474
00:42:42,280 --> 00:42:45,880
ู„ูƒู† ู„ู„ุฃุณู ุงู„ุดุฏูŠุฏ ุงู„ูŠูˆู… ุงู„ู€ immunotherapy ู„ู… ูŠุชู…
475
00:42:45,880 --> 00:42:51,180
ุชุญุฑูŠุฑู‡ุง ู„ุชูƒูˆู† ุชุฌุงุฑุจ ู…ููŠุฏุฉ ู„ู„ุณุฑุทุงู† ุณูˆุงุก ูƒุงู†ุช ุงุณุชุฎุฏู…ุช
476
00:42:51,180 --> 00:42:54,740
ู„ุญุงู„ู‡ุง ุฃูˆ ุงุณุชุฎุฏู…ุช in combination with chemotherapy
477
00:42:54,740 --> 00:43:00,000
and radiotherapy ุฃูˆ even surgery ุงู„ูŠูˆู… currently
478
00:43:00,000 --> 00:43:06,460
ูˆููŠ ูŠุนู†ูŠ ู…ุฌู…ูˆุนุฉ ูƒุจูŠุฑุฉ ู…ู† ุงู„ุฃุจุญุงุซ ูˆ ุงู„ุงุณุชุฑุงุชูŠุฌูŠุงุช
479
00:43:06,460 --> 00:43:12,110
ูˆุถุนุช for experimental immunotherapy of tumor
480
00:43:12,110 --> 00:43:19,810
ู„ู„ุงุณุชุฎุฏุงู… ูˆุทุจุนุง ุงุณุชุฎุฏู…ูˆู‡ุง ู…ู† ุฎู„ุงู„ ุฏุฑุงุณุชู‡ู… ู„ูƒูŠููŠุฉ
481
00:43:19,810 --> 00:43:27,430
ูˆุณุงุฆู„ ุชู†ุดูŠุท ุฃูˆ ู‚ุชู„ ุงู„ุฎู„ุงูŠุง ุงู„ู…ู†ุงุนูŠุฉ ุชู†ุดูŠุท ุงู„ุฎู„ุงูŠุง
482
00:43:27,430 --> 00:43:30,750
ุงู„ู…ู†ุงุนูŠุฉ ูˆ ูƒูŠููŠุฉ ู‚ุชู„ู‡ุง ุงู„ุฎู„ุงูŠุง ุงู„ุณุฑุทุงู†ูŠุฉ ูˆุฏูŠ
483
00:43:30,750 --> 00:43:32,450
ู…ูŠูƒุงู†ูŠุฒู…ุงุช ูƒู„ู‡ุง ุงุญู†ุง ุนุงุฑููŠู†ู‡ุง
484
00:43:37,710 --> 00:43:47,360
ุฃู…ุง ุจู†ุดุท ุงู„ู…ูŠูƒุงู†ุฒู… ูˆุจุงู„ุชุงู„ูŠ ุจูŠุฎุชู„ ุจุทุฑูŠู‚ุฉ ุฃูุถู„ ูŠุนู†ูŠ
485
00:43:47,360 --> 00:43:52,220
ุงู„ุฎู„ุงูŠุง ุฏูŠ ู‚ู„ู†ุง ุจู†ู†ุดุทู‡ุง ุฃูˆ ู…ุญู‚ู† ุงู„ู„ูŠ ู‡ูˆ
486
00:43:52,220 --> 00:43:56,500
cytotoxic telephosite whatever ุญุชุชุทุฑู‚ ุงู„ู‰ ู‡ุฐู‡
487
00:43:56,500 --> 00:44:00,700
ุงู„ู…ูŠูƒุงู†ูŠุฒู…ุงุช ูˆุงุญุฏ ูˆุงุญุฏ tumor specific monoclonal
488
00:44:00,700 --> 00:44:08,340
antibody ุงุณุชุฎุฏู…ูˆุง ุฃู†ุช ุฏูŠ anti CD20 ู„ุนู„ุงุฌ ุจุนุถ
489
00:44:08,340 --> 00:44:14,920
ุงู„ู„ูŠู†ููˆู…ุฉ Anti human ุฅูŠู‡ ุจุฏูŠู„ ู…ู† ุงู„ู€ Growth Factor
490
00:44:14,920 --> 00:44:17,700
Receptor for treatment of certain patients with
491
00:44:17,700 --> 00:44:22,420
breast and ovarian cancerุŸ ุทุจุนุง ู‡ุฐู‡ ุงู„ุงู†ุชูŠุจุงุฏูŠ ูƒุงู†
492
00:44:22,420 --> 00:44:27,600
ุจุฏูŠู„ Cytolysis either by Anky cell ู…ู† ุฎู„ุงู„ ุงู„ู€ FC
493
00:44:27,600 --> 00:44:34,260
receptor ูˆู…ูŠูƒุงู†ุฒู… ุงู„ู€ ADCC ุฃูˆ by complement
494
00:44:34,260 --> 00:44:39,740
activation ูˆSurface Cytolysis attachment of toxin
495
00:44:39,740 --> 00:44:45,000
such as ricin or radioactive isotopes ุจุฑุจุทูˆุง ู‡ุฐุง
496
00:44:45,000 --> 00:44:51,460
ุงู„ู€ toxin ุจุงู„ู€ antibody ูˆ ุจูŠุญู‚ู†ูˆู‡ ููŠ ุงู„ุฅู†ุณุงู†
497
00:44:51,460 --> 00:44:55,380
ูˆุจุงู„ุชุงู„ูŠ ุจูŠุจู‚ู‰ ูŠู…ุดูŠ ู„ุบุฉ muscle specific for tumor
498
00:44:55,380 --> 00:44:58,000
cell ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตู„ ุงู„ู€ tumor cell ูˆ ู‡ู†ุงูƒ ุจูŠุนู…ู„
499
00:44:58,000 --> 00:45:04,000
direct killing ู„ู€ ุงู„ู€ cell xenogenic antibody ุทุจุนุง
500
00:45:04,000 --> 00:45:10,120
ุฃุฎุฐูˆุง ู…ู† ุงู„ู€ mouse ุงู†ุชูŠุจุงุฏูŠ ุทุจุนุง ู‡ูˆ ุนุจุงุฑุฉ ุนู† ู†ุงูˆุณ
501
00:45:10,120 --> 00:45:16,160
ุฃู†ุชูŠุจุงุฏูŠ ู„ูƒู† ุงู„ู€ Fc portion ุจูŠุฑูŠ ูƒูˆู…ุจูŠู„ูŠู† ุฏูŠ ุฃู†ู‡ูŠ
502
00:45:16,160 --> 00:45:20,580
ุชูƒู†ูˆู„ูˆุฌูŠ ุฎู„ูˆู‡ุง humanize their constant region
503
00:45:20,580 --> 00:45:26,860
ูˆุจุงู„ุชุงู„ูŠ ุญู‚ู† ุนุดุงู† ูŠู‚ู„ู„ู‡ู… ุงู„ู€ immunogenicity ุชุจุนุชู‡
504
00:45:26,860 --> 00:45:31,560
ุจุงูŠ specific ุงู†ุชูŠุจุงุฏูŠ ู‡ุฐุง ุนุจุงุฑุฉ ุนู† ุงู†ุชูŠุจุงุฏูŠ
505
00:45:31,560 --> 00:45:38,580
ุงู„ุงู†ุชูŠุจุงุฏูŠ ู„ู‡ two Fab ูˆุงุญุฏุฉ ุฎู„ูˆู‡ุง ุทุจุนุง ุจุฑุถู‡ by
506
00:45:38,580 --> 00:45:42,240
recombinant DNA technology ุงู„ู…ูˆุถูˆุน ูˆุงุญุฏุฉ ุฎู„ูˆู‡ุง
507
00:45:42,240 --> 00:45:46,180
specific for tumor antigen ูˆุงู„ุชุงู†ูŠุฉ specific for
508
00:45:46,180 --> 00:45:52,480
ุงูŠุด for T cell ุฃูˆ NK cell ุฃูˆ whatever ู…ุงุดูŠ
509
00:45:52,480 --> 00:45:59,890
ูˆุจุงู„ุชุงู„ูŠ ู‚ุฑุจูˆุง ุงู„ู€ tumor cell ู…ู† ุงู„ุฎู„ูŠุฉ ุงู„ู…ู†ุงุนูŠุฉ
510
00:45:59,890 --> 00:46:02,850
ุงู„ู„ูŠ ู‡ูŠ ุงู„ู€ cytotoxic T- lymphocyte ุฃูˆ ุงู„ุงู†ูƒูŠ ุณูŠู„
511
00:46:02,850 --> 00:46:09,110
ุฅุฐุง ูƒุงู† specific ู„ู„ู€ Fc portion ุฃูˆ Fc receptor ุงู„ู„ูŠ
512
00:46:09,110 --> 00:46:12,530
ู…ูˆุฌูˆุฏ ุนู„ู‰ ุณุทุญ ุงู„ุงู†ูƒูŠ ุณูŠู„ ูุจุงู„ุชุงู„ูŠ ุงู„ุงู†ูƒูŠ ุณูŠู„ ุงู„ูŠูˆู…
513
00:46:12,530 --> 00:46:19,350
ู‚ุฑุจ both cells ุณูˆุงุก ุงู„ู€ cytotoxic ุฃูˆ ุงู„ุงู†ูƒูŠ ุณูŠู„ ุดุฑุท
514
00:46:19,350 --> 00:46:24,620
ู†ุฌุงุญ ุงู„ู„ูŠ ู‡ูˆ ูˆุธูŠูุชู‡ุง ุงู„ู„ูŠ ู‡ูˆ cell to cell contact
515
00:46:24,620 --> 00:46:27,700
ูู‡ูˆ ู‚ุฑู‘ุจูˆุง ุงู„ุฎู„ูŠุฉ ู…ู† ุจุนุถ ูˆุจุงู„ุชุงู„ูŠ ุจูŠุญุตู„ ููŠ direct
516
00:46:27,700 --> 00:46:34,820
license ุงู„ู€ recombinant diffusion protein ุงู„ู„ูŠ ู‡ูˆ
517
00:46:34,820 --> 00:46:41,260
ุจุนุถ ุงู„ู…ุฑุงุช ุจูŠุนู…ู„ูˆุง protein ุนุจุงุฑุฉ ุนู† cytokine ู…ุน
518
00:46:41,260 --> 00:46:46,550
antitumor antibody ูˆุจูŠุณู…ูˆู‡ immunocytokine immuno
519
00:46:46,550 --> 00:46:50,450
ูŠุนู†ูŠ ุงู†ุชูŠุจุงุฏูŠ ูˆ cytokine ู…ู† immunoglobulin ุทุจุนุง ูˆ
520
00:46:50,450 --> 00:46:54,250
cytokine ู…ู† cytokine ุจูŠุนู…ู„ูˆู„ู‡ู… ุนู„ู‰ ุดูƒู„ ุจุฑูˆุชูŠู† ูˆ
521
00:46:54,250 --> 00:46:58,490
ุจูŠูƒูˆู†ูˆุง as a fusion protein concentrate ูˆุจุงู„ุชุงู„ูŠ
522
00:46:58,490 --> 00:47:05,170
ุจูŠุตูŠุฑ ุจูŠุดุชุบู„ ุนู„ู‰ ุงู„ู€ tumor cell ุจุดูƒู„ ุฃูุถู„ ุณุงุนุฉ
523
00:47:05,170 --> 00:47:12,280
ุชูƒุณูƒ ุชูŠู„ูŠู†ููˆุณุงุนุฉ ุชุชุงุฎุฏ ูˆ ุจุชุชู†ู…ู‰ ุจุฑุงู…ุงุดูŠ ู‡ุฐู‡
524
00:47:12,280 --> 00:47:17,940
ุงู„ุฎู„ุงูŠุง ุชุณุชุทูŠุน ุฃู† ุชู‚ุชู„ ู…ุจุงุดุฑุฉ ุงู„ู€ tumor cell ูˆ
525
00:47:17,940 --> 00:47:23,380
ุฎุตูˆุตุง ุฃู†ู‡ ุนู†ุฏู‡ุง ุงู„ู‚ุฏุฑุฉ ุฃู†ู‡ุง ุชุชูƒูˆู† cost emulatory
526
00:47:23,380 --> 00:47:30,840
molecule ุฒูŠ CDAT86 ุฃูˆ cytokine ุทุจุนุง ุทุจุนุง ุทุจุนุง
527
00:47:30,840 --> 00:47:38,980
ุทุจุนุง
528
00:47:38,980 --> 00:47:40,920
ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง
529
00:47:40,920 --> 00:47:44,620
ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง ุทุจุนุง
530
00:47:47,550 --> 00:47:51,530
ุจู†ุดุทูˆู‡ุง ุจุญูƒูŠ ุฃู† ุงู„ู€dendritic cell already ู…ุฑุชุจุท
531
00:47:51,530 --> 00:47:55,530
ุจุงุด ู…ู† ุฎู„ุงู„ MHC class 1 ู…ูˆู„ูŠูƒูˆู„ูŠุฉ ุนู„ู‰ ุงู„ุณุทุญุฉ ุจุงู„
532
00:47:55,530 --> 00:48:01,310
antigenic peptide ุฃูˆ tumor antigen ูˆุจุงู„ุชุงู„ูŠ ุจูŠุตูŠุฑ
533
00:48:01,310 --> 00:48:08,410
ุชุนุฑู ุฃูˆ ู…ุชู†ุดูŠุท ู„ู„ุชูŠุงุชูŠูƒ ุณุงูŠุชูˆุชูƒุณูŠูƒ ู„ูŠู…ููˆุณุงูŠุช ุฃูƒุซุฑ
534
00:48:08,410 --> 00:48:12,170
ุฅุฐุง ู‡ุฐู‡ highly efficient antigen presenting cell
535
00:48:12,170 --> 00:48:18,490
normally express high level of cell surface ูˆุจุงู„ุชุงู„ูŠ
536
00:48:18,490 --> 00:48:25,890
ุจูŠุตูŠุฑ ููŠู‡ ู†ุดุงุท ุฃูƒุซุฑ ู„ู€ T-cells.Dentritic cells are
537
00:48:25,890 --> 00:48:31,630
either directly loaded ุจุงู„ุจูŠุจุชุงูŠุฏ ุฏูŠ ุจู†ุญู…ู„ู‡ุง
538
00:48:31,630 --> 00:48:37,550
ู…ุจุงุดุฑุฉ ุจุงู„ุจูŠุจุชุงูŠุฏ ุงู„ู€ tumor ุจูŠุจุชุงูŠุฏ ูŠุนู†ูŠ ุฎู„ุงู„ tumor
539
00:48:37,550 --> 00:48:40,730
cell lysate ุฃูˆ
540
00:48:41,970 --> 00:48:46,030
ู‡ูŠ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
541
00:48:46,030 --> 00:48:47,070
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
542
00:48:47,070 --> 00:48:51,950
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
543
00:48:51,950 --> 00:48:55,450
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
544
00:48:55,450 --> 00:49:00,250
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
545
00:49:00,250 --> 00:49:00,630
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
546
00:49:00,630 --> 00:49:03,210
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡
547
00:49:03,210 --> 00:49:11,590
ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠู†ุงูŠู‡ ุชุชุนุงู…ู„ ู…ุน ู…ุตุงุฏุฑ ุฏูŠTumor
548
00:49:11,590 --> 00:49:14,270
Antigen That Have Been Molecularly Characterized
549
00:49:14,270 --> 00:49:19,070
Active Vaccination ู†ูุณู‡ุง ู†ุณุชุฎุฏู… Recombinant
550
00:49:19,070 --> 00:49:22,990
Vaccine Which
551
00:49:22,990 --> 00:49:26,770
Have Been Developed Using Vaccinia Listeria Or
552
00:49:26,770 --> 00:49:33,310
Virus-Like Particle ุทุจุนุง ู‡ุฐุง ุนุจุงุฑุฉ ุนู† Active
553
00:49:33,310 --> 00:49:41,480
Immunization ู…ู† ุฎู„ุงู„ ุฃูŠุถุง ุญู‚ู†ู‚ DNA ุจู„ุงุฒู…ูŠุฏ
554
00:49:41,480 --> 00:49:48,080
Constructs ุงู„ู„ูŠ ู‡ูˆ DNA Vaccine ุจูŠุณู…ูˆู‡ ูˆุงู„ู‡ุฏู ู…ู†
555
00:49:48,080 --> 00:49:57,020
ุฐู„ูƒ ู‡ูˆ ุฃู† ูŠูƒูˆู† specific ู„ู„ู€ tumor antigen and
556
00:49:57,020 --> 00:50:05,300
expressed by muscle cell ูุฃู†ุง ุฏูุน ุนู† Vaccine ู…ูˆุฌูˆุฏ
557
00:50:05,300 --> 00:50:06,880
ููŠ ุงู„ู€ DNA
558
00:50:13,350 --> 00:50:17,030
which is unique to tumor antigen ูŠุนู†ูŠ ูˆุจุงู„ุชุงู„ูŠ
559
00:50:17,030 --> 00:50:20,910
ุจูŠุตูŠุฑ ููŠ expression ู„ู‡ุฐุง ุงู„ู€ vaccine ู‡ุฐุง ุงู„ู€ tumor
560
00:50:20,910 --> 00:50:24,670
antigen ุฃูƒุซุฑ ูˆุจุงู„ุชุงู„ูŠ ุจูŠุจู‚ู‰ ููŠู‡ ุชู†ุดูŠุท ู„ูŠุด ู„ู„ุฎู„ุงูŠุง
561
00:50:24,670 --> 00:50:28,610
ุงู„ู…ู†ุงุนูŠุฉ ุฃูƒุซุฑ ููŠ ุจุนุถ ุงู„ุญุงู„ุงุช ุดูˆ ุจูŠุนู…ู„ูˆุง ุจูŠุญู‚ู„ูˆุง
562
00:50:28,610 --> 00:50:35,430
ุฌูŠู†ุงุช ุฃูŠุถุง ู…ุณุฆูˆู„ุฉ ุนู† ุชุตู†ูŠุน cytokine ุฒูŠ GM-CSF IL2
563
00:50:35,430 --> 00:50:44,730
IL12 ูƒู„ ู…ุง ุฏูˆู„ if they introduced ุจูŠุญุณู†ูˆุง
564
00:50:44,730 --> 00:50:47,150
ุงู„ู€ presentation of tumor antigen by the enteric
565
00:50:47,150 --> 00:50:56,430
cell at the site of injection augmentation
566
00:50:56,430 --> 00:51:04,710
of specific anticancer immunity ู‡ูˆ ุทุจุนุง ู‡ุฐุง by
567
00:51:04,710 --> 00:51:12,580
stimulation of macrophage using BCG ุฃูˆ ูƒูˆุฑูŠู†ูˆ
568
00:51:12,580 --> 00:51:20,080
ุจูƒุชูŠุฑูŠุงู… ุจุงุฑููˆู† ุทุจุนุง ู…ุซุงู„ ุนู„ู‰ ุฐู„ูƒ ููŠ ุงุณุชุฎุฏุงู… ุงู„ู€
569
00:51:20,080 --> 00:51:24,060
BCG for treating patient with residual superficial
570
00:51:24,060 --> 00:51:28,480
urinary bladder cancer ุจุญู‚ ู†ู‡ูˆ repeated
571
00:51:28,480 --> 00:51:31,300
installation of live mycobacterium into the
572
00:51:31,300 --> 00:51:38,490
bladder ู…ู† ุฎู„ุงู„ ูƒุงุชูŠุชุฑ ุจุนุฏ ุงู„ุนู…ู„ูŠุฉ ุจุนุฏ ู…ุง ูŠุนู…ู„ูˆู‡ ุงู„ู€
573
00:51:38,490 --> 00:51:46,570
section ู„ู‡ุง ุฃุซุจุชุช ู†ุฌุงุญ ูˆุจุชุนุชุจุฑ treatment of
574
00:51:46,570 --> 00:51:54,970
choice for superficial bladder cancer ู„ุงุฒู… ูŠูƒูˆู†
575
00:51:54,970 --> 00:52:01,630
ุฎุงุฑุฌูŠ synthetic molecule ุฃูŠุถุง ู‡ุจูŠู† ูŠูˆุฒ ุฒูŠ ุงู„ุจุนูŠุฑุงู†
576
00:52:01,630 --> 00:52:09,710
ูˆ ุงู„ู€ copilumar ูˆ ุงู„ู€ maleic anhydride diphenyl ether ูˆุนุฏุฉ
577
00:52:09,710 --> 00:52:16,530
these induce interferon production ูˆุงูŠุถุง ุจุนุถ ุงู„ู€
578
00:52:16,530 --> 00:52:19,690
herbal extracts have been used to stimulate the
579
00:52:19,690 --> 00:52:28,650
immune response ู…ู†ู‡ุง ุงู„ุฌู†ุณูŠู†ุฌ ูˆุงู„ุฅูŠุดูŠู†ูŠุณูŠุง
580
00:52:31,840 --> 00:52:35,500
ุงู„ู€ trials are also in progress on the effect of
581
00:52:35,500 --> 00:52:40,820
various cytokines ุฒูŠ ุงู„ู€ interferon alpha, beta,
582
00:52:41,020 --> 00:52:47,220
gamma ุนู„ู‰ ุงู„ู€ 1,2,2,3,4,5,12 tumor necrosis factor
583
00:52:47,220 --> 00:52:54,540
ูˆุขุฎุฑ ุฅู…ุง singly or in combination on tumor
584
00:52:54,540 --> 00:52:56,600
regression
585
00:52:59,960 --> 00:53:04,680
ุนุดุฑุฉ lag cell ูˆ ุงู„ู€ tumor infiltrate lymphocytes
586
00:53:04,680 --> 00:53:09,680
ุฃูŠุถุง ุงุณุชุฎุฏู…ู‡ู… ููŠ treatment of cancer with variable
587
00:53:09,680 --> 00:53:15,020
results lag cells are produced in vitro by
588
00:53:15,020 --> 00:53:21,060
cultivation ุจูŠุนู…ู„ูˆู„ู‡ุง culturing ุจุงู„ู€ IL-2 ูˆ
589
00:53:21,060 --> 00:53:25,000
ุจูŠุนู…ู„ูˆู„ู‡ุง reinfusion to the patient ูˆ ุชุนู…ู„
590
00:53:25,000 --> 00:53:28,620
dramatic improvement in the have been used
591
00:53:34,260 --> 00:53:37,700
ุฃูŠุถุง ุงู„ู€ documented success ูƒุงู†ุช ุฃูŠุถุง ู…ู‚ุงู„ุฉ
592
00:53:37,700 --> 00:53:42,940
ุจุงุณุชุฎุฏุงู… tumor infiltrate lymphocyte ู„ู…ุง ู†ู‚ู„ู†ุงู‡ุง
593
00:53:42,940 --> 00:53:48,280
ู„ู…ุฑุถู‰ ุนู†ุฏู‡ู… melanoma ูˆุฌุฏูˆุง ุฃู† ู‡ุฐู‡ ุงู„ู€ lymphocyte
594
00:53:48,280 --> 00:53:53,140
ุทุจุนุง ู…ู…ูƒู† ุชุชุงุฎุฏ by removal from tumor biopsy
595
00:53:53,140 --> 00:53:58,640
expanded in vitro ูŠุนู†ูŠ ู‚ุจู„ูˆู„ู‡ุง ู‚ุฏูˆู‡ุง ูˆู‚ุจู„ูˆู„ู‡ุง
596
00:53:58,640 --> 00:54:04,380
culturing ููŠ ูˆุฌูˆุฏ IL-2 ูˆุฑุฌุนูˆู‡ุง ุซุงู†ูŠ ูˆุนู„ูŠ ุงู„ู…ุฑูŠุถ
597
00:54:04,380 --> 00:54:09,600
ูˆุฌุฏูˆุง ุฃู†ู‡ ููŠู‡ Anti-Tumor Activity Higher Many
598
00:54:09,600 --> 00:54:20,900
Times Than Lag Cell ูˆ ู‡ุฐู‡ ู‚ู„ู„ุช ู…ู† ุงู„ุนู„ุงุฌ
599
00:54:20,900 --> 00:54:26,260
tumor immunoprophylaxis ูŠุนู†ูŠ ุนุดุงู† ู†ู…ู†ุน ุงู„ู„ูŠ ู‡ูˆ
600
00:54:26,260 --> 00:54:29,460
prophylactic treatment for tumor
601
00:54:35,430 --> 00:54:38,850
ุจุงุณุชุฎุฏุงู… ุชู‚ู†ูŠุฉ ุงู…ูŠูˆู†ูŠุฉ ูŠุนู†ูŠ ุงู…ูŠูˆู†ูŠุฉ ุถุฏ ุงู„ููŠุฑูˆุณ
602
00:54:38,850 --> 00:54:42,590
ุงู„ุฃู†ูƒูˆุฌูŠู†ูŠูƒูŠ ูƒุงู†ุช
603
00:54:42,590 --> 00:54:47,330
ู…ูู‡ูˆู…ุฉ ููŠ ุงู„ูƒู„ุจ ุญู‚ุง ุฃู†ู‡ู… ููŠ ุงู„ููŠุฑูˆุณ ุงู„ุฃู†ูƒูˆุฌูŠู†ูŠูƒูŠ
604
00:54:47,330 --> 00:54:52,850
ุฃูŠุถุง ุงู…ูŠูˆู†ูŠุฉ ุถุฏ ุนุถู„ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช
605
00:54:52,850 --> 00:54:54,310
ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช
606
00:54:54,310 --> 00:54:55,950
ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช
607
00:54:55,950 --> 00:54:59,590
ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช
608
00:54:59,590 --> 00:54:59,670
ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช
609
00:54:59,670 --> 00:55:02,690
ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญูŠูˆุงู†ุงุช ุงู„ุญุฃูˆ ุจูŠุนุทูˆุง tumor cell in
610
00:55:02,690 --> 00:55:06,570
which replication has been blocked ู…ุงููŠุด
611
00:55:06,570 --> 00:55:10,290
replication ุฃูˆ enzymatically modified surface
612
00:55:10,290 --> 00:55:13,910
membrane tumor cell ุฃูˆ extract of antigen from the
613
00:55:13,910 --> 00:55:18,110
surface of tumor cell ูƒู„ู‡ุง ุนุจุงุฑุฉ ุนู† antigen ู„ูƒู†
614
00:55:18,110 --> 00:55:22,840
ู…ู„ุนูˆููŠุจุนูŠุด ุฃู†ู‡ ู…ุงูŠุตุงุฑุด ููŠู‡ ุงู„ูˆู‡ ุงู„ู„ูŠ ู‡ูˆ
615
00:55:22,840 --> 00:55:28,380
replication ููŠ ุงู„ .. ูˆุจุงู„ุชุงู„ูŠ ู‡ูˆ ุจุฑุน ุงู„ู€ energy
616
00:55:28,380 --> 00:55:34,980
ุจูŠุนุทูŠ ุนุณุงุณูŠ ูŠู‚ูˆู… ุงู„ุฌู‡ุงุฒ ุงู„ู…ู†ุงุนูŠ ุนู†ุฏ ุงู„ุฅู†ุณุงู†
617
00:55:34,980 --> 00:55:37,880
despite success in protection of experimental
618
00:55:37,880 --> 00:55:42,720
animal ููŠ ุงู„ู€ animal ู…ุงุดูŠ efficacy of menopreflexes
619
00:55:42,720 --> 00:55:44,040
for protection of human
620
00:55:51,920 --> 00:55:57,020
ุฃูˆ ุญู‚ูŠู‚ูŠุฉ ุนู„ู‰ ุงู„ู€ human ุจุงู„ู†ุณุจุฉ ู„ู„ุชุนุงู…ู„
621
00:55:57,020 --> 00:56:01,600
ุงู„ู€ ุจุฑูˆููŠู„ุงูƒุชูŠูƒูŠ ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„
622
00:56:01,600 --> 00:56:05,840
ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human
623
00:56:05,840 --> 00:56:05,920
ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„
624
00:56:05,920 --> 00:56:06,100
ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human
625
00:56:06,100 --> 00:56:09,740
ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„ ุงู„ู€ human ุจุดูƒู„
626
00:56:09,740 --> 00:56:10,620
ุงู„ู‡ูŠูˆู…ุงู† ุจูŠุด